Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention | Clínica e Investigación en Arteriosclerosis (English Edition)

array:23 ["pii" => "S2529912322000419" "issn" => "25299123" "doi" => "10.1016/j.artere.2022.06.007" "estado" => "S300" "fechaPublicacion" => "2022-07-01" "aid" => "638" "copyrightAnyo" => "2022" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Clin Investig Arterioscler. 2022;34:219-28" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0214916822000365" "issn" => "02149168" "doi" => "10.1016/j.arteri.2022.03.003" "estado" => "S300" "fechaPublicacion" => "2022-07-01" "aid" => "638" "copyright" => "Sociedad Española de Arteriosclerosis" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Clin Invest Arterioscl. 2022;34:219-28" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "ARTÍCULO ESPECIAL" "titulo" => "Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "219" "paginaFinal" => "228" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figura 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 859 "Ancho" => 2175 "Tamanyo" => 204416 ] ] "descripcion" => array:1 [ "es" => "Estrategia para el tratamiento de la hipertensión arterial (HTA) sin complicación clínica asociada. ARA II: antagonista de los receptores de la angiotensina ii; BB: betabloqueante; CA: calcioantagonista; CI: cardiopatía isquémica; comp: comprimido; FA: fibrilación auricular; IC: insuficiencia cardiaca; IECA: inhibidor de la enzima de conversión de la angiotensina; PAS: presión arterial sistólica." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Carlos Brotons, Miguel Camafort, María del Mar Castellanos, Albert Clarà, Olga Cortés, Angel Diaz Rodriguez, Roberto Elosua, Manuel Gorostidi, Antonio M. Hernández, María Herranz, Soledad Justo, Carlos Lahoz, Pilar Niño, Vicente Pallarés-Carratalá, Juan Pedro-Botet, Antonio Pérez Pérez, Miguel Angel Royo-Bordonada, Rafael Santamaria, Ricard Tresserras, Alberto Zamora, Inés Zuza, Pedro Armario" "autores" => array:22 [ 0 => array:2 [ "nombre" => "Carlos" "apellidos" => "Brotons" ] 1 => array:2 [ "nombre" => "Miguel" "apellidos" => "Camafort" ] 2 => array:2 [ "nombre" => "María del Mar" "apellidos" => "Castellanos" ] 3 => array:2 [ "nombre" => "Albert" "apellidos" => "Clarà" ] 4 => array:2 [ "nombre" => "Olga" "apellidos" => "Cortés" ] 5 => array:2 [ "nombre" => "Angel" "apellidos" => "Diaz Rodriguez" ] 6 => array:2 [ "nombre" => "Roberto" "apellidos" => "Elosua" ] 7 => array:2 [ "nombre" => "Manuel" "apellidos" => "Gorostidi" ] 8 => array:2 [ "nombre" => "Antonio M." "apellidos" => "Hernández" ] 9 => array:2 [ "nombre" => "María" "apellidos" => "Herranz" ] 10 => array:2 [ "nombre" => "Soledad" "apellidos" => "Justo" ] 11 => array:2 [ "nombre" => "Carlos" "apellidos" => "Lahoz" ] 12 => array:2 [ "nombre" => "Pilar" "apellidos" => "Niño" ] 13 => array:2 [ "nombre" => "Vicente" "apellidos" => "Pallarés-Carratalá" ] 14 => array:2 [ "nombre" => "Juan" "apellidos" => "Pedro-Botet" ] 15 => array:2 [ "nombre" => "Antonio" "apellidos" => "Pérez Pérez" ] 16 => array:2 [ "nombre" => "Miguel Angel" "apellidos" => "Royo-Bordonada" ] 17 => array:2 [ "nombre" => "Rafael" "apellidos" => "Santamaria" ] 18 => array:2 [ "nombre" => "Ricard" "apellidos" => "Tresserras" ] 19 => array:2 [ "nombre" => "Alberto" "apellidos" => "Zamora" ] 20 => array:2 [ "nombre" => "Inés" "apellidos" => "Zuza" ] 21 => array:2 [ "nombre" => "Pedro" "apellidos" => "Armario" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529912322000419" "doi" => "10.1016/j.artere.2022.06.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912322000419?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916822000365?idApp=UINPBA00004N" "url" => "/02149168/0000003400000004/v2_202311230440/S0214916822000365/v2_202311230440/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2529912322000420" "issn" => "25299123" "doi" => "10.1016/j.artere.2022.06.008" "estado" => "S300" "fechaPublicacion" => "2022-07-01" "aid" => "637" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Clin Investig Arterioscler. 2022;34:229-43" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Review article" "titulo" => "Nuclear receptor NOR-1 (Neuron-derived Orphan Receptor-1) in pathological vascular remodelling" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "229" "paginaFinal" => "243" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "El receptor nuclear NOR-1 (Neuron-derived Orphan Receptor-1) en el remodelado vascular patológico" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0025" "etiqueta" => "Figure 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1502 "Ancho" => 3333 "Tamanyo" => 503119 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0025" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Animals overexpressing human NOR-1 in VSMCs (TgNOR-1VSMC) are more susceptible to develop angiotensin II (AngII)-induced abdominal aortic aneurysm (AAA). (A) Shown is the experimental design in which AAA formation and gene expression (by microarrays) in the aorta of TgNORVSMC and control animals were compared after infusing AngII (1000 ng/kg/min) via osmotic minipumps for 28 days. Differential expression analysis detected 968 and 544 genes whose expression was increased or decreased, respectively.<a class="elsevierStyleCrossRef" href="#bib0055">11</a> B) Gene Set Enrichment Analysis (GSEA) pathway analysis identified clusters of differentially regulated genes related to, among other processes, inflammation/immune response, extracellular matrix remodelling, DNA damage response, and synaptic signalling, the latter including genes coding for enzymes of the catecholamine synthesis pathway such as tyrosine hydroxylase. FDR: False discovery rate; NES: Normalized enrichment score." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Carme Ballester-Servera, Laia Cañes, Judith Alonso, Lidia Puertas, Manel Taurón, Cristina Rodríguez, José Martínez-González" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Carme" "apellidos" => "Ballester-Servera" ] 1 => array:2 [ "nombre" => "Laia" "apellidos" => "Cañes" ] 2 => array:2 [ "nombre" => "Judith" "apellidos" => "Alonso" ] 3 => array:2 [ "nombre" => "Lidia" "apellidos" => "Puertas" ] 4 => array:2 [ "nombre" => "Manel" "apellidos" => "Taurón" ] 5 => array:2 [ "nombre" => "Cristina" "apellidos" => "Rodríguez" ] 6 => array:2 [ "nombre" => "José" "apellidos" => "Martínez-González" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0214916822000341" "doi" => "10.1016/j.arteri.2022.03.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916822000341?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912322000420?idApp=UINPBA00004N" "url" => "/25299123/0000003400000004/v2_202311240533/S2529912322000420/v2_202311240533/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S2529912322000547" "issn" => "25299123" "doi" => "10.1016/j.artere.2022.07.005" "estado" => "S300" "fechaPublicacion" => "2022-07-01" "aid" => "650" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Clin Investig Arterioscler. 2022;34:216-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Editorial" "titulo" => "Gut microbiota: An indispensable tool in the fight against cardiovascular disease" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "216" "paginaFinal" => "218" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La microbiota intestinal: una herramienta indispensable en la lucha contra la enfermedad cardiovascular" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Isabel Moreno-Indias" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Isabel" "apellidos" => "Moreno-Indias" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912322000547?idApp=UINPBA00004N" "url" => "/25299123/0000003400000004/v2_202311240533/S2529912322000547/v2_202311240533/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "Original article" "titulo" => "Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "219" "paginaFinal" => "228" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Carlos Brotons, Miguel Camafort, María del Mar Castellanos, Albert Clarà, Olga Cortés, Angel Diaz Rodriguez, Roberto Elosua, Manuel Gorostidi, Antonio M. Hernández, María Herranz, Soledad Justo, Carlos Lahoz, Pilar Niño, Vicente Pallarés-Carratalá, Juan Pedro-Botet, Antonio Pérez Pérez, Miguel Angel Royo-Bordonada, Rafael Santamaria, Ricard Tresserras, Alberto Zamora, Inés Zuza, Pedro Armario" "autores" => array:22 [ 0 => array:4 [ "nombre" => "Carlos" "apellidos" => "Brotons" "email" => array:1 [ 0 => "cbrotons@eapsardenya.cat" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Miguel" "apellidos" => "Camafort" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "María del Mar" "apellidos" => "Castellanos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Albert" "apellidos" => "Clarà" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "Olga" "apellidos" => "Cortés" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "Angel" "apellidos" => "Diaz Rodriguez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "f" "identificador" => "aff0030" ] ] ] 6 => array:3 [ "nombre" => "Roberto" "apellidos" => "Elosua" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "g" "identificador" => "aff0035" ] ] ] 7 => array:3 [ "nombre" => "Manuel" "apellidos" => "Gorostidi" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "h" "identificador" => "aff0040" ] ] ] 8 => array:3 [ "nombre" => "Antonio M." "apellidos" => "Hernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "i" "identificador" => "aff0045" ] ] ] 9 => array:3 [ "nombre" => "María" "apellidos" => "Herranz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "j" "identificador" => "aff0050" ] ] ] 10 => array:3 [ "nombre" => "Soledad" "apellidos" => "Justo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "k" "identificador" => "aff0055" ] ] ] 11 => array:3 [ "nombre" => "Carlos" "apellidos" => "Lahoz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 12 => array:3 [ "nombre" => "Pilar" "apellidos" => "Niño" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "l" "identificador" => "aff0060" ] ] ] 13 => array:3 [ "nombre" => "Vicente" "apellidos" => "Pallarés-Carratalá" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "f" "identificador" => "aff0030" ] ] ] 14 => array:3 [ "nombre" => "Juan" "apellidos" => "Pedro-Botet" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "m" "identificador" => "aff0065" ] ] ] 15 => array:3 [ "nombre" => "Antonio Pérez" "apellidos" => "Pérez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "i" "identificador" => "aff0045" ] ] ] 16 => array:3 [ "nombre" => "Miguel Angel" "apellidos" => "Royo-Bordonada" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "n" "identificador" => "aff0070" ] ] ] 17 => array:3 [ "nombre" => "Rafael" "apellidos" => "Santamaria" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "h" "identificador" => "aff0040" ] ] ] 18 => array:3 [ "nombre" => "Ricard" "apellidos" => "Tresserras" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "o" "identificador" => "aff0075" ] ] ] 19 => array:3 [ "nombre" => "Alberto" "apellidos" => "Zamora" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "m" "identificador" => "aff0065" ] ] ] 20 => array:3 [ "nombre" => "Inés" "apellidos" => "Zuza" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "k" "identificador" => "aff0055" ] ] ] 21 => array:3 [ "nombre" => "Pedro" "apellidos" => "Armario" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "p" "identificador" => "aff0080" ] ] ] ] "afiliaciones" => array:16 [ 0 => array:3 [ "entidad" => "Sociedad Española de Medicina de Familia y Comunitaria-semFYC, Barcelona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Sociedad Española de Medicina Interna, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Sociedad Española de Neurología, Barcelona, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Sociedad Española de Angiología y Cirugía Vascular, Madrid, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Asociación Española Pediatría de Atención Primaria, Madrid, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Sociedad Española de Médicos de Atención Primaria-SEMERGEN, Madrid, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Sociedad Española de Epidemiología, Barcelona, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Sociedad Española de Nefrología, Santander, Spain" "etiqueta" => "h" "identificador" => "aff0040" ] 8 => array:3 [ "entidad" => "Sociedad Española de Diabetes, Madrid, Spain" "etiqueta" => "i" "identificador" => "aff0045" ] 9 => array:3 [ "entidad" => "Federación de Asociaciones de Enfermería Comunitaria y Atención Primaria-FAECAP, Madrid, Spain" "etiqueta" => "j" "identificador" => "aff0050" ] 10 => array:3 [ "entidad" => "Ministerio de Sanidad, Madrid, Spain" "etiqueta" => "k" "identificador" => "aff0055" ] 11 => array:3 [ "entidad" => "Sociedad Española de Medicina y Seguridad del Trabajo, Madrid, Spain" "etiqueta" => "l" "identificador" => "aff0060" ] 12 => array:3 [ "entidad" => "Sociedad Española de Arteriosclerosis, Barcelona, Spain" "etiqueta" => "m" "identificador" => "aff0065" ] 13 => array:3 [ "entidad" => "Instituto de Salud Carlos III, Madrid, Spain" "etiqueta" => "n" "identificador" => "aff0070" ] 14 => array:3 [ "entidad" => "Sociedad Española de Salud Pública y Administración Sanitaria-SESPAS, Barcelona, Spain" "etiqueta" => "o" "identificador" => "aff0075" ] 15 => array:3 [ "entidad" => "Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial, Madrid, Spain" "etiqueta" => "p" "identificador" => "aff0080" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:9 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Adapted from Figure 6, page 26. Eur Heart J. 2021;42:3227−3337. doi: https://doi.org/10.1093/eurheartj/ehab484." "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 4151 "Ancho" => 2925 "Tamanyo" => 934541 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Vascular risk algorithm and therapeutic targets in apparently healthy patients. LDL-C, low-density lipoprotein cholesterol; CV, cardiovascular; CVD, cardiovascular disease; SBP, systolic blood pressure; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2-Older Persons." ] ] ] "textoCompleto" => "IntroductionThe new European Guidelines for Cardiovascular Prevention<a class="elsevierStyleCrossRef" href="#bib0005">1</a> were published 5 years after the last guidelines of 2016,<a class="elsevierStyleCrossRef" href="#bib0010">2</a> although an update was made in 2020,<a class="elsevierStyleCrossRef" href="#bib0015">3</a> on which the Spanish Interdisciplinary Vascular Prevention Committee (CEIPV) made a critical commentary.<a class="elsevierStyleCrossRef" href="#bib0020">4</a>The 2021 guidelines were developed by 13 European scientific societies and have introduced significant new features, which are discussed below. In addition to the individual approach to cardiovascular prevention, they place special emphasis on the population and public health strategy, which the CEIPV has always considered highly relevant, as reflected in the documents published and the programmes of the biennial conferences organised by the Ministry of Health. These are more complex than previous guidelines because they seek a more personalised approach, which certainly reflects the phenotypic diversity of the patients seen in clinical practice.Vascular risk assessmentThe new guidelines on cardiovascular prevention recommend systematically calculating vascular risk (VR) in all adults with any VR factor, which could also be in men>40 years and women>50 years, and repeated every 5 years. Some publications<a class="elsevierStyleCrossRef" href="#bib0025">5</a> have highlighted potential risks of labelling people as low VR, as they may be given a false sense of security that they are protected from vascular disease, which might compromise their motivation to prevent risk factors. Most of the population fall into these risk bands (moderate or low), where more cases of vascular disease occur in absolute numbers. Therefore, it is essential to promote health lifestyles in the entire population.The therapeutic targets for low-density lipoprotein cholesterol (LDL-C), blood pressure (BP), and blood glucose have not changed from the previous guidelines, but the way they are controlled in individuals has been modified in a stepwise manner (steps 1 and 2). This approach is not new as a concept, and is intended to reflect the usual clinical practice of the progressive intensification of therapeutic strategies as part of a shared decision-making process between healthcare professionals and patients. It is always recommended to get to step 2, and treatment will be intensified according to 10-year and lifetime risk, treatment benefit, comorbidities, frailty, and patient preferences. However, we should not forget that according to the results of the EUROASPIRE study,<a class="elsevierStyleCrossRef" href="#bib0030">6</a> conducted in 27 European countries, we are still a long way from achieving therapeutic objectives (71% of people with coronary heart disease had LDL-C≥70 mg/dl), and this stepwise strategy could encourage inertia, compromising the earliest possible achievement of objectives, especially in patients with high or very high CVR. Therefore, in patients at high or very high VR, particularly those who have already experienced a vascular event, we continue to recommend strict achievement of LDL-C targets along with the ≥50% reduction in LDL-C from baseline in a single step and as soon as possible. Regardless of risk, smoking cessation, adopting a healthy lifestyle and a systolic blood pressure (SBP)<160 mmHg are recommended for all individuals.For the first time, the guidelines present a new model for calculating risk – SCORE2<a class="elsevierStyleCrossRef" href="#bib0035">7</a> and SCORE2-OP<a class="elsevierStyleCrossRef" href="#bib0040">8</a> – which has been calibrated for 4 European regions according to vascular mortality rates; Spain is one of the low VR countries. This tool allows calculation of the risk of vascular morbidity and mortality in the next 10 years (myocardial infarction, stroke, and vascular mortality) in men and women between 40 and 89 years of age. The coloured tables in the guidelines (using SBP, age, sex, smoking, and non-high-density lipoprotein cholesterol) can be used, the European Society of Cardiology App or the tool available on the web (<a href="https://u-prevent.com">https://u-prevent.com</a>), where total and high-density lipoprotein cholesterol can be entered. These applications can also be used to calculate lifetime VR (LIFE-CV model) and the benefits of treatment in terms of years of life gained without vascular disease. In addition, there are specific tools for risk calculation in people with diabetes (ADVANCE risk score or DIAL model) and with established vascular disease (SMART REACH score or SMART REACH model).Vascular risk categories according to SCORE2/SCORE2-OP in apparently healthy peopleAnother substantial development is the establishment of different risk thresholds according to age, as shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>, in contrast to previous versions, which established a single risk threshold, to avoid undertreatment in young people and overtreatment in older people, as the long-term benefit of treating VR factors is greater in younger patients.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>It is recommended that all very high-risk individuals should be treated, and treatment should be considered for those at high risk, based on risk modifiers, lifetime risk, treatment benefits and personal preferences.The VR calculation and treatment algorithms for VR factors for apparently healthy individuals, patients with atherosclerotic vascular disease and patients with diabetes are presented in <a class="elsevierStyleCrossRefs" href="#fig0005">Figs. 1–3</a>. Patients with chronic kidney disease (CKD) will be considered high or very high risk based on glomerular filtration rate and albumin/creatinine ratio (ACR). Patients with familial hypercholesterolaemia are considered high risk.<elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><elsevierMultimedia ident="fig0015"></elsevierMultimedia>The importance of communication with the patient is emphasised and an informed discussion of risk and therapeutic benefits, tailored to the needs of the individual, is recommended. In particular, the need for lifelong VR use is mentioned, especially in younger individuals, and the lifelong benefits after intervention or vascular age.Risk modifiersFew risk modifiers meet the criteria to be considered in the VR calculation: to improve prediction (discrimination and reclassification), to have a clear public health impact (number of patients to be treated or screened) and to be feasible for implementation in clinical practice. The most relevant modifiers are summarised in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>.<elsevierMultimedia ident="tbl0010"></elsevierMultimedia>Developments in lifestyle recommendationsThe CEIPV has adapted the recommendations of the new guidelines based on those of the World Health Organisation and the Ministry of Health. They recommend:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">none-Engaging in at least 150−300 min of moderate physical activity per week (or 75−150 min of vigorous activity or an equivalent combination of both) and performing muscle strengthening, bone mass improvement, and flexibility activities at least 2 days per week.<a class="elsevierStyleCrossRefs" href="#bib0045">9,10</a></li><li class="elsevierStyleListItem" id="lsti0010">none-Reducing sedentary periods, with breaks for activity every 1 h or 2 h, increasing active transport and limiting screen time.<a class="elsevierStyleCrossRefs" href="#bib0045">9,10</a></li><li class="elsevierStyleListItem" id="lsti0015">none-Eating a healthy and sustainable diet based on fresh, seasonal, and local foods: including at least 5 portions of fruit and vegetables a day, wholegrain cereals, prioritise vegetable protein (pulses, nuts) and fish, preferably oily fish, incorporating eggs, chicken, natural yoghurt, and milk in moderation, and avoiding red or processed meat, convenience foods, industrial pastries, and sugary drinks.<a class="elsevierStyleCrossRef" href="#bib0055">11</a></li><li class="elsevierStyleListItem" id="lsti0020">none-Avoiding alcohol, as this is the only recommendation that avoids the risks associated with alcohol consumption. If consumed, the less the better, and always below the low-risk consumption limits: 10 g alcohol/day (one standard drink unit) in women and 20 g/day (2 standard drink units) in men,<a class="elsevierStyleCrossRef" href="#bib0060">12</a> leaving a few days a week alcohol free and avoiding binge drinking; consumption should be completely avoided in children under 18 years of age and during pregnancy and breastfeeding.</li></ul>Cessation of tobacco use in all its forms, including tobacco products and related products such as e-cigarettes, and avoid of environmental exposure to tobacco smoke.Developments in the treatment of risk factors in patients with vascular diseaseLipidsA stepwise approach to intensifying treatment is advised in otherwise healthy individuals with high or very high VR and in patients with vascular disease or diabetes, considering VR, treatment benefit, risk modifiers, co-morbidities, and personal preferences. In patients who have had vascular disease, in order to reach therapeutic LDL-C targets as soon as possible, it is recommended to proceed directly to step 2 (see section on VR). High-intensity statins are recommended in people at very high risk or with vascular disease, and if LDL-C targets are not achieved, ezetimibe should be added, and if targets are still not achieved, a PCSK9 inhibitor should be added. Although this recommendation agrees with meeting targets in 2 steps, it is difficult to achieve reductions≥50% in LDL-C, unless with maximal doses of atorvastatin and rosuvastatin. The available evidence suggests changing the terminology of “high-potency statins” to “high-intensity cholesterol-lowering therapy”.<a class="elsevierStyleCrossRef" href="#bib0065">13</a> Thus, the first option in patients with high or very high VR could be to use non-maximal doses of statins (atorvastatin 40 mg or rosuvastatin 10 mg) associated with ezetimibe, which help therapeutic goals to be met with better tolerance and adherence. The addition of n-3 fatty acids (ethyl icosapentate 2 × 2 g/day) to statin therapy could be considered in high or very high-risk patients with mild/moderate hypertriglyceridaemia (triglyceride levels above 150 mg/dl).HypertensionIn contrast to the American guidelines (ACC/AHA 2017), the same classical threshold is still recommended to define hypertension (HTN), classifying it as optimal BP, normal BP, normal-high BP, and HT grades 1–3 (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). The Spanish Society of Hypertension-Spanish League for Combating High Blood Pressure has already published a position paper justifying the desirability of maintaining this same cut-off point to define HTN.<a class="elsevierStyleCrossRef" href="#bib0070">14</a><elsevierMultimedia ident="tbl0015"></elsevierMultimedia>It is recommended to initiate treatment in individuals with grade 1 HTN considering VR, lifetime benefit, and the presence of target organ involvement. However, despite evidence of the benefit of lowering BP in reducing vascular morbidity and mortality, BP monitoring in Europe and other parts of the world is suboptimal, especially in low- and middle-income countries,<a class="elsevierStyleCrossRef" href="#bib0075">15</a> and has worsened in recent years.<a class="elsevierStyleCrossRef" href="#bib0080">16</a> Although the cause is multifactorial, poor adherence plays an important role. The recommended strategy for initial treatment remains the use of drug combinations, with an angiotensin-converting enzyme inhibitor or an angiotensin II receptor antagonist in combination with a thiazide diuretic or a long half-life calcium antagonist (<a class="elsevierStyleCrossRef" href="#fig0020">Fig. 4</a>). A recent meta-analysis has shown that this strategy improves adherence and control rate in patients with HTN.<a class="elsevierStyleCrossRef" href="#bib0085">17</a><elsevierMultimedia ident="fig0020"></elsevierMultimedia>Diabetes mellitusMetformin is recommended as first-line treatment of diabetes mellitus (DM) with monitoring of renal function, especially in patients without vascular disease, chronic renal failure, or heart failure. In these cases, in addition to the use or non-use of metformin, treatment with glucagon-like peptide receptor agonists type 1 or sodium-glucose cotransporter inhibitors type 2 that have demonstrated a reduction in vascular and renal events is recommended. In patients with DM and CKD, sodium-glucose cotransporter type 2 inhibitors are recommended due to their vascular and renal benefits. In patients with DM and reduced ejection fraction, sodium-glucose cotransporter type 2 inhibitors are recommended to reduce hospitalisation for heart failure and vascular deaths.Chronic kidney diseaseCKD, as defined by estimated glomerular filtration rate (eGFR) and urine ACR, determines prognosis (<a class="elsevierStyleCrossRef" href="#fig0025">Fig. 5</a>). In patients without DM, an eGFR<30 ml/min/1.73 m2 or an eGFR 30−44 ml/min/1.73 m2 with an ACR>30 mg/g determines a very high risk of vascular events, in the same way as a previous vascular event. On the other hand, an eGFR of 30−44 ml/min/1.73 m2 and an ACR<30 mg/g or an eGFR of 45−59 ml/min/1. 73 m2 and an ACR of 30−300 mg/g, or an eGFR≥60 ml/min/1.73 m2 and an ACR>300 mg/g determines an elevated risk of vascular events.<a class="elsevierStyleCrossRef" href="#bib0090">18</a> In patients with DM, severe target organ damage is considered to be an eFGR<45 ml/min/1.73 m2, or an eGFR of 45−59 ml/min/1.73 m2 and an ACR of 30−300 mg/g, or an ACR>300 mg/g; similarly, the presence of microvascular complications in 3 different sites confers a very high VR. In patients with CKD, general smoking cessation and improved lifestyle measures, SBP control targets between 130 and 140 mmHg and DBP<80 mmHg according to tolerance, and LDL-C targets less than 70 mg/dl or 55 mg/dl in patients with high or very high VR are recommended. In patients with DM and diabetic kidney disease, the use of hypoglycaemic drugs with recognised renal protective effects is recommended.<elsevierMultimedia ident="fig0025"></elsevierMultimedia>Antithrombotic therapyThe addition of a second antithrombotic drug (P2Y12 platelet receptor inhibitor or low-dose rivaroxaban) to aspirin should be considered for secondary prevention of vascular disease in patients at high ischaemic and low haemorrhagic risk. Combination therapy with aspirin and low-dose rivaroxaban could be considered in patients with diabetes and peripheral arterial disease. Treatment with low-dose colchicine (.5 mg/day) could be considered in secondary prevention of vascular disease if other VR factors are inadequately controlled or in the case of recurrent ischaemic events despite optimal treatment.Population-based prevention strategiesMuch greater emphasis is placed on health policy as a population-based prevention strategy. The aim is to reduce the attributable risk of risk factors, i.e., the burden of vascular disease that can be prevented by eliminating or reducing the prevalence of each factor. These strategies are based on Geoffrey Rose’s Prevention Paradox, according to which small shifts in the population distribution of risk factors to the left have a large impact on the overall burden of disease.<a class="elsevierStyleCrossRef" href="#bib0095">19</a> Guidelines and other recommendations from international bodies such as the World Health Organisation<a class="elsevierStyleCrossRefs" href="#bib0100">20–23</a> propose the most cost-effective population-based interventions to create environments that promote healthy lifestyles by modifying risk factors such as physical inactivity, unhealthy diet, tobacco, and alcohol consumption,<a class="elsevierStyleCrossRef" href="#bib0120">24</a> exposure to air and noise pollution<a class="elsevierStyleCrossRef" href="#bib0125">25</a> (especially from road traffic), and by acting on climate change. In addition, different methods (governmental, media and education, labelling and information, financial incentives), settings (schools, workplace, community) and actions are described for each of them, supported with a level of evidence and a class of recommendation. The goal, and the task for national, regional, and local authorities, is to make a healthy lifestyle easy, creating environments where the default choices are health-promoting.Recommendations for promoting physical activity and reducing sedentary lifestyles include urban planning measures to facilitate active and healthy mobility, active transport and increasing the availability of spaces and equipment that encourage physical activity in schools and community settings. To promote healthy eating, legislative measures are included to ban or reduce trans fats, reduce calorie intake, salt, added sugars and saturated fats in prepared foods and beverages, fiscal measures (taxation or incentives) on some foods and beverages, and availability of healthy meals on menus and in food vending machines in schools and workplaces. Recommendations, mainly legislative, are also included to reduce tobacco and alcohol consumption: regulation of consumption in public places, availability and sale, advertising, labelling and packaging, pricing policies, and the implementation of educational campaigns.<a class="elsevierStyleCrossRefs" href="#bib0105">21–26</a> Finally, measures are recommended to reduce emissions of small particles and gaseous pollutants, the use of solid fuels and road traffic, and to limit carbon dioxide emissions to reduce CV morbidity and mortality.The population-based approach offers many benefits, such as reducing the gap in health inequalities, preventing other non-communicable diseases that have common risk factors and determinants with vascular events, such as cancer, lung disease, and type 2 DM, and saving the health and social costs of vascular events that have been prevented.Conflict of interestsThe authors have no conflict of interests to declare." "textoCompletoSecciones" => array:1 [ "secciones" => array:14 [ 0 => array:3 [ "identificador" => "xres2021537" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1730595" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres2021536" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1730596" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Vascular risk assessment" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Vascular risk categories according to SCORE2/SCORE2-OP in apparently healthy people" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Risk modifiers" ] 8 => array:2 [ "identificador" => "sec0025" "titulo" => "Developments in lifestyle recommendations" ] 9 => array:3 [ "identificador" => "sec0030" "titulo" => "Developments in the treatment of risk factors in patients with vascular disease" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0035" "titulo" => "Lipids" ] 1 => array:2 [ "identificador" => "sec0040" "titulo" => "Hypertension" ] ] ] 10 => array:3 [ "identificador" => "sec0045" "titulo" => "Diabetes mellitus" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0050" "titulo" => "Chronic kidney disease" ] 1 => array:2 [ "identificador" => "sec0055" "titulo" => "Antithrombotic therapy" ] ] ] 11 => array:2 [ "identificador" => "sec0060" "titulo" => "Population-based prevention strategies" ] 12 => array:2 [ "identificador" => "sec0065" "titulo" => "Conflict of interests" ] 13 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2022-03-21" "fechaAceptado" => "2022-03-28" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1730595" "palabras" => array:9 [ 0 => "Prevention and control" 1 => "Vascular diseases" 2 => "Clinical Practice Guidelines" 3 => "Healthy diet" 4 => "Arterial hypertension" 5 => "Diabetes" 6 => "Lipid control" 7 => "Smoking" 8 => "Cardiovascular risk" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1730596" "palabras" => array:9 [ 0 => "Prevención y control" 1 => "Enfermedades vasculares" 2 => "Guías de Práctica Clínicas" 3 => "Dieta saludable" 4 => "Hipertensión arterial" 5 => "Diabetes" 6 => "Control de lípidos" 7 => "Tabaco" 8 => "Riesgo cardiovascular" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease (CVD) prevention in clinical practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global CVD risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-Cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (Step 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After Step 1, considering proceeding to the intensified goals of Step 2 is mandatory, and this intensification will be based on 10-year CVD risk, lifetime CVD risk and treatment benefit, comorbidities and patient preferences.The updated SCORE algorithm—SCORE2, SCORE-OP— is recommended in these guidelines, which estimates an individual’s 10-year risk of fatal and non-fatal CVD events (myocardial infarction, stroke) in healthy men and women aged 40–89 years. Another new and important recommendation is the use of different categories of risk according different age groups (<50, 50−69, ≥70 years).Different flow charts of CVD risk and risk factor treatment in apparently healthy persons, in patients with established atherosclerotic CVD, and in diabetic patients are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "Presentamos la adaptación española de las Guías Europeas de Prevención Cardiovascular 2021. En esta actualización además del abordaje individual, se pone mucho más énfasis en las políticas sanitarias como estrategia de prevención poblacional. Se recomienda el cálculo del riesgo vascular de manera sistemática a todas las personas adultas con algún factor de riesgo vascular. Los objetivos terapéuticos para el colesterol LDL, la presión arterial y la glucemia no han cambiado respecto a las anteriores guías, pero se recomienda alcanzar estos objetivos de forma escalonada (etapas 1 y 2). Se recomienda llegar siempre hasta la etapa 2, y la intensificación del tratamiento dependerá del riesgo a los 10 años y de por vida, del beneficio del tratamiento, de las comorbilidades, de la fragilidad y de las preferencias de los pacientes. Las guías presentan por primera vez un nuevo modelo para calcular el riesgo -SCORE2 y SCORE2-OP de morbimortalidad vascular en los próximos 10 años (infarto de miocardio, ictus y mortalidad vascular) en hombres y mujeres entre 40 y 89 años. Otra de las novedades sustanciales es el establecimiento de diferentes umbrales de riesgo dependiendo de la edad (<50, 50−69, ≥70 años).Se presentan diferentes algoritmos de cálculo del riesgo vascular y tratamiento de los factores de riesgo vascular para personas aparentemente sanas, pacientes con diabetes y pacientes con enfermedad vascular aterosclerótica. Los pacientes con enfermedad renal crónica se considerarán de riesgo alto o muy alto según la tasa del filtrado glomerular y el cociente albúmina/creatinina. Se incluyen innovaciones en las recomendaciones sobre los estilos de vida, adaptadas a las recomendaciones del Ministerio de Sanidad, así como aspectos novedosos relacionados con el control de los lípidos, la presión arterial, la diabetes y la insuficiencia renal crónica." ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Brotons C, Camafort M, Castellanos MdM, Clarà A, Cortés O, Diaz Rodriguez A, et al. Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021. Clin Investig Arterioscl. 2022;73:219–228." ] ] "multimedia" => array:8 [ 0 => array:9 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Adapted from Figure 6, page 26. Eur Heart J. 2021;42:3227−3337. doi: https://doi.org/10.1093/eurheartj/ehab484." "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 4151 "Ancho" => 2925 "Tamanyo" => 934541 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Vascular risk algorithm and therapeutic targets in apparently healthy patients. LDL-C, low-density lipoprotein cholesterol; CV, cardiovascular; CVD, cardiovascular disease; SBP, systolic blood pressure; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2-Older Persons." ] ] 1 => array:9 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Adapted from Figure 7, page 27, Eur Heart J. 2021;42:3227−3337. doi: https://doi.org/10.1093/eurheartj/ehab484." "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2621 "Ancho" => 2508 "Tamanyo" => 431388 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Therapeutic target and pharmacological treatment algorithm in patients with established vascular disease. LDL-C: Low density lipoprotein cholesterol; CV: cardiovascular; DAPT: dual antiplatelet therapy; DPI: dual pathway inhibition; CVD: cardiovascular disease; SBP: systolic blood pressure." ] ] 2 => array:9 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Adapted from Figure 8, page 29, Eur Heart J. 2021;42:3227−3337. doi: https://doi.org/10.1093/eurheartj/ehab484." "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 4181 "Ancho" => 2925 "Tamanyo" => 915187 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0015" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Vascular risk algorithm, therapeutic objectives, and pharmacological treatment in patients with diabetes. CVD: cardiovascular disease; DAPT: dual antiplatelet therapy; DPI: dual pathway inhibition; GLP-1RA: glucagon-like peptide-1 receptor agonists; HbAIc: glycosylated haemoglobin; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; SGLT2-i: sodium/glucose cotransporter-2 inhibitors; TOD: target organ damage." ] ] 3 => array:8 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 859 "Ancho" => 2175 "Tamanyo" => 204294 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0020" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Strategy to treat hypertension (HTN) without associated clinical complications. ACE inhibitor: angiotensin-converting enzyme inhibitor; AF: atrial fibrillation; ARA II: Angiotensin II receptor antagonists; BB: betablocker; CCB: calcium channel blocker; CHD: coronary heart disease; comp: compromised; HF: heart failure; SBP: systolic blood pressure." ] ] 4 => array:8 [ "identificador" => "fig0025" "etiqueta" => "Figure 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1080 "Ancho" => 2175 "Tamanyo" => 219853 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0025" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Chronic kidney disease related risk according to glomerular filtration rate and albuminuria categories. Areas in green: reference risk (no kidney disease if no other defining markers are present); areas in yellow: moderate risk; areas in orange: high risk; areas in red: very high risk. *Albuminuria is expressed as albumin-creatinine ratio. Guidelines Kidney Disease: Improving Global Outcomes ‒KDIGO‒ on chronic kidney disease." ] ] 5 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0030" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Risk in the next 10 years." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><50 years \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">50−69 years \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">≥70 years \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Low to moderate vascular risk \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><2.5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><7.5% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">High vascular risk \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.5 a<7.5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 a<10% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.5 a<15% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Very high vascular risk \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥7.5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥10% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥15% \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3354862.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Vascular risk categories according to age group." ] ] 6 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0035" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "BMI: body mass index; CV: cardiovascular." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Psychosocial factors: psychosocial stress is associated with increased vascular risk Ethnicity: in South Asian population, multiply the risk by 1.1−1.7, in Black Caribbean or African population, multiply by .85, and in Chinese population, multiply by .7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Imaging tests: coronary calcium or, if not, presence of carotid plaque. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Family history of premature CV disease: although this only marginally improves risk prediction, it is simple and easy to measure. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Frailty: frailty has been shown to have an independent relationship with vascular risk, but it is not recommended to be considered in risk calculation. Caution is recommended with pharmacological interventions, due to potential side effects of drug interactions, and with implantation of devices. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Socioeconomic status: lower socioeconomic class is associated with higher vascular risk. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Environmental pollution: it is recommended that patients at high or very high risk of vascular disease try to avoid prolonged exposure to high pollution \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Body composition: BMI, waist circumference and waist-to-hip ratio have been independently associated with vascular disease, although there is no evidence that they improve reclassification. However, they are simple and easy to measure. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3354861.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Risk modifiers." ] ] 7 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0040" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "BP for classification will be based on the mean of 2 or more readings, on 2 or more occasions, following standardised recommendations for quality measures. Subjects with systolic blood pressure (SBP) and diastolic blood pressure (DBP) in different categories will be classified in the highest category.Current guidelines on the diagnosis and treatment of hypertension (HTN) indicate the need to determine ambulatory BP levels by ambulatory blood pressure monitoring or self-measurement of blood pressure, given the high prevalence of white-coat and masked HTN." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">BP category<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">SBP (mmHg) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">DBP (mmHg) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Optimal BP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><120 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">and \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><80 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Normal BP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">120−129 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">or \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">80−84 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Normal-high BP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">130−139 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">or \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">85−89 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Grade 1 HTN \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">140−159 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">or \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">90−99 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Grade 2 HTN \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">160−179 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">or \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100−109 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Grade 3 HTN \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥180 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">or \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥110 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Isolated systolic HTN \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">≥140 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">and \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><90 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3354860.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Definitions are based on blood pressure (BP) measured seated in the consultation." ] ] ] "descripcion" => array:1 [ "en" => "Classification of clinical BP (in consultation) according to clinical BP values." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:26 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESC Scientific Document Group, 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F.L.J. Visseren" 1 => "F. Mach" 2 => "Y.M. Smulders" 3 => "D. Carballo" 4 => "K.C. Koskinas" 5 => "M. Bäck" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehab484" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2021" "volumen" => "42" "paginaInicial" => "3227" "paginaFinal" => "3337" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34458905" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2016 European guideliness on cardiovascular disease prevention in clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.F. Piepoli" 1 => "A.W. Hoes" 2 => "S. Agewall" 3 => "C. Albus" 4 => "C. Brotons" 5 => "A.L. Catapano" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehw106" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2016" "volumen" => "37" "paginaInicial" => "2315" "paginaFinal" => "2381" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27222591" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update on cardiovascular prevention in clinical practice: a position paper of the European Association of Preventive Cardiology of the European Society of Cardiology" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.F. Piepoli" 1 => "A. Abreu" 2 => "C. Albus" 3 => "M. Ambrosetti" 4 => "C. Brotons" 5 => "A.L. Catapano" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Eur J Prev Cardiol" "fecha" => "2020" "volumen" => "27" "paginaInicial" => "181" "paginaFinal" => "205" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comentario del CEIPV a la actualización de las Guías Europeas de Prevención Vascular en la Práctica Clínica" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Armario" 1 => "C. Brotons" 2 => "R. Elosua" 3 => "M. Alonso de Leciñana" 4 => "A. Castro" 5 => "A. Clarà" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Rev Esp Salud Pública" "fecha" => "2020" "volumen" => "94" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "on behalf of the Stroke Experts Collaboration Group Primary stroke prevention worldwide: translating evidence into action" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.O. Owolabi" 1 => "A.G. Thrif" 2 => "A. Mahal" 3 => "M. Ishida" 4 => "S. Martin" 5 => "W.D. Johnson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2468-2667(21)00230-9" "Revista" => array:6 [ "tituloSerie" => "Lancet Public Health" "fecha" => "2022" "volumen" => "7" "paginaInicial" => "e74" "paginaFinal" => "85" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34756176" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EUROASPIRE V collaborators; Writing Committee; Scientific Steering/Executive Committee; Coordinating centre; Diabetes centre; Data management centre; Statistical analysis centre; Central laboratory; Study centres, organisations, investigators and other research personnel (National Coordinators in each country are indicated by asterisk. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. De Backer" 1 => "P. Jankowski" 2 => "K. Kotseva" 3 => "E. Mirrakhimov" 4 => "Ž Reiner" 5 => "L. Rydén" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.atherosclerosis.2019.03.014" "Revista" => array:6 [ "tituloSerie" => "Atherosclerosis" "fecha" => "2019" "volumen" => "285" "paginaInicial" => "135" "paginaFinal" => "146" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31054483" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "SCORE2 working group and ESC Cardiovascular risk collaboration" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehab309" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2021" "volumen" => "42" "paginaInicial" => "2439" "paginaFinal" => "2454" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34120177" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "SCORE2-OP working group and ESC Cardiovascular risk collaboration." "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehab312" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2021" "volumen" => "42" "paginaInicial" => "2455" "paginaFinal" => "2467" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34120185" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Directrices de la OMSsobre actividad física y hábitos sedentarios" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Organización Mundial de la Salud" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:2 [ "link" => "https://apps.who.int/iris/bitstream/handle/10665/337004/9789240014817-spa.pdf" "fecha" => "2020" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ministerio de Sanidad. Recomendaciones para lapoblación sobre actividad física y reducción del seden-tarismo. Madrid: Ministerio de Sanidad. Available from: <a target="_blank" href="https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/Estrategia/Recomendaciones_ActivFisica.htm">https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/Estrategia/Recomendaciones_ActivFisica.htm</a>." ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "D. Mozaffarian" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCULATIONAHA.115.018585" "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "2016" "volumen" => "133" "paginaInicial" => "187" "paginaFinal" => "225" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26746178" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Límites de Consumo de Bajo Riesgo de Alcohol. Actualización del riesgo relacionado con los niveles de consumo de alcohol, el patrón de consumo y el tipo de bebida" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Ministerio de Sanidad" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:2 [ "link" => "https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/Prevencion/alcohol/Limites_Consumo_Bajo_Riesgo_Alcohol.htm" "fecha" => "2021" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IMPROVE-IT clinicalimplications. Should the “high-intensity cholesterol-lowering therapy” strategy replace the “high-intensity statin therapy”?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L. Masana" 1 => "J. Pedro-Botet" 2 => "F. Civeira" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.atherosclerosis.2015.03.002" "Revista" => array:6 [ "tituloSerie" => "Atherosclerosis" "fecha" => "2015" "volumen" => "240" "paginaInicial" => "161" "paginaFinal" => "162" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25795557" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Documento de la Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA) sobre las guías ACC/AHA 2017 de hipertensión arterial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Gijón-Conde" 1 => "M. Gorostidi" 2 => "M. Camafort" 3 => "M. Abad-Cardiel" 4 => "E. Martin-Rioboo" 5 => "F. Morales-Oliva" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Hipertens Riesgo Vasc" "fecha" => "2018" "volumen" => "35" "paginaInicial" => "119" "paginaFinal" => "129" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hypertension pharmacological treatment in adults: a World Health Organization Guideline Executive Summary" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Al-Makki" 1 => "D. DiPette" 2 => "P.K. Whelton" 3 => "M.H. Murad" 4 => "R.A. Mustafa" 5 => "S. Acharya" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/HYPERTENSIONAHA.121.18192" "Revista" => array:6 [ "tituloSerie" => "Hypertension" "fecha" => "2022" "volumen" => "79" "paginaInicial" => "293" "paginaFinal" => "301" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34775787" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Medication adherence and blood pressure control: a scientific statement from the American Heart Association" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N.K. Choudrhy" 1 => "I.M. Kronish" 2 => "W. Vongpatanasin" 3 => "K.C. Ferdinand" 4 => "V.N. Pavlik" 5 => "B.M. Egan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/HYP.0000000000000203" "Revista" => array:6 [ "tituloSerie" => "Hypertension" "fecha" => "2022" "volumen" => "79" "paginaInicial" => "e1" "paginaFinal" => "e14" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34615363" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adherence to single-pill versus free-equivalent combination therapy in hypertension. A systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "G. Parati" 1 => "S. Kjeldsen" 2 => "A. Coca" 3 => "W.C. Cushman" 4 => "J. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/HYPERTENSIONAHA.120.15781" "Revista" => array:6 [ "tituloSerie" => "Hypertension" "fecha" => "2021" "volumen" => "77" "paginaInicial" => "692" "paginaFinal" => "705" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33390044" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Documento de la Sociedad Española de Nefrología sobre las guías KDIGO para la evaluación y el tratamiento de la enfermedad renal crónica" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Gorostidi" 1 => "R. Santamaría" 2 => "R. Alcázar" 3 => "G. Fernández-Fresnedo" 4 => "J.M. Galcerán" 5 => "M. Goicoechea" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3265/Nefrologia.pre2014.Feb.12464" "Revista" => array:6 [ "tituloSerie" => "Nefrologia" "fecha" => "2014" "volumen" => "34" "paginaInicial" => "302" "paginaFinal" => "316" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24798565" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sick individuals and sick populations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G. Rose" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ije/14.1.32" "Revista" => array:6 [ "tituloSerie" => "Int J Epidemiol" "fecha" => "1985" "volumen" => "14" "paginaInicial" => "32" "paginaFinal" => "38" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3872850" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "«Mejores inversiones» y otras intervenciones recomendadas para la prevención y el control de las enfermedades no transmisible. Lucha contra las ENT" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Organización Mundial de la Salud" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:2 [ "link" => "https://apps.who.int/iris/bitstream/handle/10665/259351/WHO-NMH-NVI-17.9-spa.pdf?sequence=1" "fecha" => "2017" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "El paquete técnico SAFER. Un mundo libre de los daños relacionados con el alcohol" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Organización Panamericana de la Salud" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:2 [ "link" => "https://iris.paho.org/bitstream/handle/10665.2/51867/9879275321959_spa.pdf?sequence=5&isAllowed=y" "fecha" => "2020" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "WHO global air quality guidelines. Particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "World Health Organization" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2021" "editorial" => "WHO" "editorialLocalizacion" => "Geneva" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Regional Office for Europe. Environmental noise guidelines for the European Region (2018)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "World Health Organization" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:2 [ "link" => "https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/Prevencion/alcohol/docs/ConsumoAlcohol_DecisoresPoliticos.pdf" "fecha" => "2018" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consumo de alcohol: Información para decisores políticos. ¿Qué pueden hacer las administraciones públicas?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Ministerio de Sanidad" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:2 [ "link" => "https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/Prevencion/alcohol/docs/ConsumoAlcohol_DecisoresPoliticos.pdf" "fecha" => "2021" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Exposure to aircraft and road traffic noise and associations with heart disease and stroke in six European countries: a cross-sectional study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Floud" 1 => "M. Blangiardo" 2 => "C. Clark" 3 => "K. de Hoogh" 4 => "W. Babisch" 5 => "D. Houthuijs" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1476-069X-12-89" "Revista" => array:5 [ "tituloSerie" => "Environ Health" "fecha" => "2013" "volumen" => "12" "paginaInicial" => "89" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24131577" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Convenio Marco de la OMSpara el Control del Tabaco" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Organización Mundial de la Salud" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:2 [ "link" => "https://apps.who.int/iris/bitstream/handle/10665/42813/9243591010.pdf?sequence=1" "fecha" => "2003" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/25299123/0000003400000004/v2_202311240533/S2529912322000419/v2_202311240533/en/main.assets" "Apartado" => array:4 [ "identificador" => "63722" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Special Article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25299123/0000003400000004/v2_202311240533/S2529912322000419/v2_202311240533/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912322000419?idApp=UINPBA00004N"]

Statistics

Original article

Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention

Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021

Carlos Brotonsa,

Corresponding author

cbrotons@eapsardenya.cat

Corresponding author.

, Miguel Camafortb, María del Mar Castellanosc, Albert Claràd, Olga Cortése, Angel Diaz Rodriguezf, Roberto Elosuag, Manuel Gorostidih, Antonio M. Hernándezi, María Herranzj, Soledad Justok, Carlos Lahozb, Pilar Niñol, Vicente Pallarés-Carrataláf, Juan Pedro-Botetm, Antonio Pérez Pérezi, Miguel Angel Royo-Bordonadan, Rafael Santamariah, Ricard Tresserraso, Alberto Zamoram..., Inés Zuzak, Pedro ArmariopVer más

a Sociedad Española de Medicina de Familia y Comunitaria-semFYC, Barcelona, Spain

b Sociedad Española de Medicina Interna, Madrid, Spain

c Sociedad Española de Neurología, Barcelona, Spain

d Sociedad Española de Angiología y Cirugía Vascular, Madrid, Spain

e Asociación Española Pediatría de Atención Primaria, Madrid, Spain

f Sociedad Española de Médicos de Atención Primaria-SEMERGEN, Madrid, Spain

g Sociedad Española de Epidemiología, Barcelona, Spain

h Sociedad Española de Nefrología, Santander, Spain

i Sociedad Española de Diabetes, Madrid, Spain

j Federación de Asociaciones de Enfermería Comunitaria y Atención Primaria-FAECAP, Madrid, Spain

k Ministerio de Sanidad, Madrid, Spain

l Sociedad Española de Medicina y Seguridad del Trabajo, Madrid, Spain

m Sociedad Española de Arteriosclerosis, Barcelona, Spain

n Instituto de Salud Carlos III, Madrid, Spain

o Sociedad Española de Salud Pública y Administración Sanitaria-SESPAS, Barcelona, Spain

p Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial, Madrid, Spain

Read

468

Times
was read the article

Total PDF

389

Total HTML

Share statistics

 array:23 [
  "pii" => "S2529912322000419"
  "issn" => "25299123"
  "doi" => "10.1016/j.artere.2022.06.007"
  "estado" => "S300"
  "fechaPublicacion" => "2022-07-01"
  "aid" => "638"
  "copyrightAnyo" => "2022"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "fla"
  "cita" => "Clin Investig Arterioscler. 2022;34:219-28"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0214916822000365"
      "issn" => "02149168"
      "doi" => "10.1016/j.arteri.2022.03.003"
      "estado" => "S300"
      "fechaPublicacion" => "2022-07-01"
      "aid" => "638"
      "copyright" => "Sociedad Espa&#241;ola de Arteriosclerosis"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "fla"
      "cita" => "Clin Invest Arterioscl. 2022;34:219-28"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">ART&#205;CULO ESPECIAL</span>"
        "titulo" => "Comentario del CEIPV a las nuevas Gu&#237;as Europeas de Prevenci&#243;n Cardiovascular 2021"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "219"
            "paginaFinal" => "228"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0020"
            "etiqueta" => "Figura 4"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr4.jpeg"
                "Alto" => 859
                "Ancho" => 2175
                "Tamanyo" => 204416
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Estrategia para el tratamiento de la hipertensi&#243;n arterial &#40;HTA&#41; sin complicaci&#243;n cl&#237;nica asociada&#46; ARA II&#58; antagonista de los receptores de la angiotensina <span class="elsevierStyleSmallCaps">ii</span>&#59; BB&#58; betabloqueante&#59; CA&#58; calcioantagonista&#59; CI&#58; cardiopat&#237;a isqu&#233;mica&#59; comp&#58; comprimido&#59; FA&#58; fibrilaci&#243;n auricular&#59; IC&#58; insuficiencia cardiaca&#59; IECA&#58; inhibidor de la enzima de conversi&#243;n de la angiotensina&#59; PAS&#58; presi&#243;n arterial sist&#243;lica&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Carlos Brotons, Miguel Camafort, Mar&#237;a del Mar Castellanos, Albert Clar&#224;, Olga Cort&#233;s, Angel Diaz Rodriguez, Roberto Elosua, Manuel Gorostidi, Antonio M&#46; Hern&#225;ndez, Mar&#237;a Herranz, Soledad Justo, Carlos Lahoz, Pilar Ni&#241;o, Vicente Pallar&#233;s-Carratal&#225;, Juan Pedro-Botet, Antonio P&#233;rez P&#233;rez, Miguel Angel Royo-Bordonada, Rafael Santamaria, Ricard Tresserras, Alberto Zamora, In&#233;s Zuza, Pedro Armario"
            "autores" => array:22 [
              0 => array:2 [
                "nombre" => "Carlos"
                "apellidos" => "Brotons"
              ]
              1 => array:2 [
                "nombre" => "Miguel"
                "apellidos" => "Camafort"
              ]
              2 => array:2 [
                "nombre" => "Mar&#237;a del Mar"
                "apellidos" => "Castellanos"
              ]
              3 => array:2 [
                "nombre" => "Albert"
                "apellidos" => "Clar&#224;"
              ]
              4 => array:2 [
                "nombre" => "Olga"
                "apellidos" => "Cort&#233;s"
              ]
              5 => array:2 [
                "nombre" => "Angel"
                "apellidos" => "Diaz Rodriguez"
              ]
              6 => array:2 [
                "nombre" => "Roberto"
                "apellidos" => "Elosua"
              ]
              7 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "Gorostidi"
              ]
              8 => array:2 [
                "nombre" => "Antonio M&#46;"
                "apellidos" => "Hern&#225;ndez"
              ]
              9 => array:2 [
                "nombre" => "Mar&#237;a"
                "apellidos" => "Herranz"
              ]
              10 => array:2 [
                "nombre" => "Soledad"
                "apellidos" => "Justo"
              ]
              11 => array:2 [
                "nombre" => "Carlos"
                "apellidos" => "Lahoz"
              ]
              12 => array:2 [
                "nombre" => "Pilar"
                "apellidos" => "Ni&#241;o"
              ]
              13 => array:2 [
                "nombre" => "Vicente"
                "apellidos" => "Pallar&#233;s-Carratal&#225;"
              ]
              14 => array:2 [
                "nombre" => "Juan"
                "apellidos" => "Pedro-Botet"
              ]
              15 => array:2 [
                "nombre" => "Antonio"
                "apellidos" => "P&#233;rez P&#233;rez"
              ]
              16 => array:2 [
                "nombre" => "Miguel Angel"
                "apellidos" => "Royo-Bordonada"
              ]
              17 => array:2 [
                "nombre" => "Rafael"
                "apellidos" => "Santamaria"
              ]
              18 => array:2 [
                "nombre" => "Ricard"
                "apellidos" => "Tresserras"
              ]
              19 => array:2 [
                "nombre" => "Alberto"
                "apellidos" => "Zamora"
              ]
              20 => array:2 [
                "nombre" => "In&#233;s"
                "apellidos" => "Zuza"
              ]
              21 => array:2 [
                "nombre" => "Pedro"
                "apellidos" => "Armario"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2529912322000419"
          "doi" => "10.1016/j.artere.2022.06.007"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912322000419?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916822000365?idApp=UINPBA00004N"
      "url" => "/02149168/0000003400000004/v2_202311230440/S0214916822000365/v2_202311230440/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S2529912322000420"
    "issn" => "25299123"
    "doi" => "10.1016/j.artere.2022.06.008"
    "estado" => "S300"
    "fechaPublicacion" => "2022-07-01"
    "aid" => "637"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "rev"
    "cita" => "Clin Investig Arterioscler. 2022;34:229-43"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>"
      "titulo" => "Nuclear receptor NOR-1 &#40;Neuron-derived Orphan Receptor-1&#41; in pathological vascular remodelling"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "229"
          "paginaFinal" => "243"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "El receptor nuclear NOR-1 &#40;<span class="elsevierStyleItalic">Neuron-derived Orphan Receptor-1</span>&#41; en el remodelado vascular patol&#243;gico"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0025"
          "etiqueta" => "Figure 5"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr5.jpeg"
              "Alto" => 1502
              "Ancho" => 3333
              "Tamanyo" => 503119
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0025"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Animals overexpressing human NOR-1 in VSMCs &#40;TgNOR-1<span class="elsevierStyleSup">VSMC</span>&#41; are more susceptible to develop angiotensin II &#40;AngII&#41;-induced abdominal aortic aneurysm &#40;AAA&#41;&#46; &#40;A&#41; Shown is the experimental design in which AAA formation and gene expression &#40;by microarrays&#41; in the aorta of TgNOR<span class="elsevierStyleSup">VSMC</span> and control animals were compared after infusing AngII &#40;1000 ng&#47;kg&#47;min&#41; via osmotic minipumps for 28 days&#46; Differential expression analysis detected 968 and 544 genes whose expression was increased or decreased&#44; respectively&#46;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> B&#41; Gene Set Enrichment Analysis &#40;GSEA&#41; pathway analysis identified clusters of differentially regulated genes related to&#44; among other processes&#44; inflammation&#47;immune response&#44; extracellular matrix remodelling&#44; DNA damage response&#44; and synaptic signalling&#44; the latter including genes coding for enzymes of the catecholamine synthesis pathway such as tyrosine hydroxylase&#46; FDR&#58; False discovery rate&#59; NES&#58; Normalized enrichment score&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Carme Ballester-Servera, Laia Ca&#241;es, Judith Alonso, Lidia Puertas, Manel Taur&#243;n, Cristina Rodr&#237;guez, Jos&#233; Mart&#237;nez-Gonz&#225;lez"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "Carme"
              "apellidos" => "Ballester-Servera"
            ]
            1 => array:2 [
              "nombre" => "Laia"
              "apellidos" => "Ca&#241;es"
            ]
            2 => array:2 [
              "nombre" => "Judith"
              "apellidos" => "Alonso"
            ]
            3 => array:2 [
              "nombre" => "Lidia"
              "apellidos" => "Puertas"
            ]
            4 => array:2 [
              "nombre" => "Manel"
              "apellidos" => "Taur&#243;n"
            ]
            5 => array:2 [
              "nombre" => "Cristina"
              "apellidos" => "Rodr&#237;guez"
            ]
            6 => array:2 [
              "nombre" => "Jos&#233;"
              "apellidos" => "Mart&#237;nez-Gonz&#225;lez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0214916822000341"
        "doi" => "10.1016/j.arteri.2022.03.002"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916822000341?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912322000420?idApp=UINPBA00004N"
    "url" => "/25299123/0000003400000004/v2_202311240533/S2529912322000420/v2_202311240533/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "S2529912322000547"
    "issn" => "25299123"
    "doi" => "10.1016/j.artere.2022.07.005"
    "estado" => "S300"
    "fechaPublicacion" => "2022-07-01"
    "aid" => "650"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Clin Investig Arterioscler. 2022;34:216-8"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
      "titulo" => "Gut microbiota&#58; An indispensable tool in the fight against cardiovascular disease"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "216"
          "paginaFinal" => "218"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "La microbiota intestinal&#58; una herramienta indispensable en la lucha contra la enfermedad cardiovascular"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Isabel Moreno-Indias"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Isabel"
              "apellidos" => "Moreno-Indias"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912322000547?idApp=UINPBA00004N"
    "url" => "/25299123/0000003400000004/v2_202311240533/S2529912322000547/v2_202311240533/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
    "titulo" => "Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "219"
        "paginaFinal" => "228"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Carlos Brotons, Miguel Camafort, Mar&#237;a del Mar Castellanos, Albert Clar&#224;, Olga Cort&#233;s, Angel Diaz Rodriguez, Roberto Elosua, Manuel Gorostidi, Antonio M&#46; Hern&#225;ndez, Mar&#237;a Herranz, Soledad Justo, Carlos Lahoz, Pilar Ni&#241;o, Vicente Pallar&#233;s-Carratal&#225;, Juan Pedro-Botet, Antonio P&#233;rez P&#233;rez, Miguel Angel Royo-Bordonada, Rafael Santamaria, Ricard Tresserras, Alberto Zamora, In&#233;s Zuza, Pedro Armario"
        "autores" => array:22 [
          0 => array:4 [
            "nombre" => "Carlos"
            "apellidos" => "Brotons"
            "email" => array:1 [
              0 => "cbrotons@eapsardenya.cat"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Miguel"
            "apellidos" => "Camafort"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Mar&#237;a del Mar"
            "apellidos" => "Castellanos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Albert"
            "apellidos" => "Clar&#224;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Olga"
            "apellidos" => "Cort&#233;s"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Angel"
            "apellidos" => "Diaz Rodriguez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Roberto"
            "apellidos" => "Elosua"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Manuel"
            "apellidos" => "Gorostidi"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Antonio M&#46;"
            "apellidos" => "Hern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Mar&#237;a"
            "apellidos" => "Herranz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "Soledad"
            "apellidos" => "Justo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">k</span>"
                "identificador" => "aff0055"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "Carlos"
            "apellidos" => "Lahoz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          12 => array:3 [
            "nombre" => "Pilar"
            "apellidos" => "Ni&#241;o"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">l</span>"
                "identificador" => "aff0060"
              ]
            ]
          ]
          13 => array:3 [
            "nombre" => "Vicente"
            "apellidos" => "Pallar&#233;s-Carratal&#225;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          14 => array:3 [
            "nombre" => "Juan"
            "apellidos" => "Pedro-Botet"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">m</span>"
                "identificador" => "aff0065"
              ]
            ]
          ]
          15 => array:3 [
            "nombre" => "Antonio P&#233;rez"
            "apellidos" => "P&#233;rez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          16 => array:3 [
            "nombre" => "Miguel Angel"
            "apellidos" => "Royo-Bordonada"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">n</span>"
                "identificador" => "aff0070"
              ]
            ]
          ]
          17 => array:3 [
            "nombre" => "Rafael"
            "apellidos" => "Santamaria"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          18 => array:3 [
            "nombre" => "Ricard"
            "apellidos" => "Tresserras"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">o</span>"
                "identificador" => "aff0075"
              ]
            ]
          ]
          19 => array:3 [
            "nombre" => "Alberto"
            "apellidos" => "Zamora"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">m</span>"
                "identificador" => "aff0065"
              ]
            ]
          ]
          20 => array:3 [
            "nombre" => "In&#233;s"
            "apellidos" => "Zuza"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">k</span>"
                "identificador" => "aff0055"
              ]
            ]
          ]
          21 => array:3 [
            "nombre" => "Pedro"
            "apellidos" => "Armario"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">p</span>"
                "identificador" => "aff0080"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:16 [
          0 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Medicina de Familia y Comunitaria-semFYC&#44; Barcelona&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Medicina Interna&#44; Madrid&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Neurolog&#237;a&#44; Barcelona&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Angiolog&#237;a y Cirug&#237;a Vascular&#44; Madrid&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Asociaci&#243;n Espa&#241;ola Pediatr&#237;a de Atenci&#243;n Primaria&#44; Madrid&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de M&#233;dicos de Atenci&#243;n Primaria-SEMERGEN&#44; Madrid&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Epidemiolog&#237;a&#44; Barcelona&#44; Spain"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Nefrolog&#237;a&#44; Santander&#44; Spain"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Diabetes&#44; Madrid&#44; Spain"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
          9 => array:3 [
            "entidad" => "Federaci&#243;n de Asociaciones de Enfermer&#237;a Comunitaria y Atenci&#243;n Primaria-FAECAP&#44; Madrid&#44; Spain"
            "etiqueta" => "j"
            "identificador" => "aff0050"
          ]
          10 => array:3 [
            "entidad" => "Ministerio de Sanidad&#44; Madrid&#44; Spain"
            "etiqueta" => "k"
            "identificador" => "aff0055"
          ]
          11 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Medicina y Seguridad del Trabajo&#44; Madrid&#44; Spain"
            "etiqueta" => "l"
            "identificador" => "aff0060"
          ]
          12 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Arteriosclerosis&#44; Barcelona&#44; Spain"
            "etiqueta" => "m"
            "identificador" => "aff0065"
          ]
          13 => array:3 [
            "entidad" => "Instituto de Salud Carlos III&#44; Madrid&#44; Spain"
            "etiqueta" => "n"
            "identificador" => "aff0070"
          ]
          14 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Salud P&#250;blica y Administraci&#243;n Sanitaria-SESPAS&#44; Barcelona&#44; Spain"
            "etiqueta" => "o"
            "identificador" => "aff0075"
          ]
          15 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Hipertensi&#243;n-Liga Espa&#241;ola para la Lucha contra la Hipertensi&#243;n Arterial&#44; Madrid&#44; Spain"
            "etiqueta" => "p"
            "identificador" => "aff0080"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Comentario del CEIPV a las nuevas Gu&#237;as Europeas de Prevenci&#243;n Cardiovascular 2021"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:9 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "fuente" => "Adapted from Figure 6&#44; page 26&#46; Eur Heart J&#46; 2021&#59;42&#58;3227&#8722;3337&#46; doi&#58; <span class="elsevierStyleInterRef" id="intr0005" href="https://doi.org/10.1093/eurheartj/ehab484">https&#58;&#47;&#47;doi&#46;org&#47;10&#46;1093&#47;eurheartj&#47;ehab484</span>&#46;"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 4151
            "Ancho" => 2925
            "Tamanyo" => 934541
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Vascular risk algorithm and therapeutic targets in apparently healthy patients&#46; LDL-C&#44; low-density lipoprotein cholesterol&#59; CV&#44; cardiovascular&#59; CVD&#44; cardiovascular disease&#59; SBP&#44; systolic blood pressure&#59; SCORE2&#44; Systematic Coronary Risk Estimation 2&#59; SCORE2-OP&#44; Systematic Coronary Risk Estimation 2-Older Persons&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">The new European Guidelines for Cardiovascular Prevention<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> were published 5 years after the last guidelines of 2016&#44;<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> although an update was made in 2020&#44;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> on which the Spanish Interdisciplinary Vascular Prevention Committee &#40;CEIPV&#41; made a critical commentary&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The 2021 guidelines were developed by 13 European scientific societies and have introduced significant new features&#44; which are discussed below&#46; In addition to the individual approach to cardiovascular prevention&#44; they place special emphasis on the population and public health strategy&#44; which the CEIPV has always considered highly relevant&#44; as reflected in the documents published and the programmes of the biennial conferences organised by the Ministry of Health&#46; These are more complex than previous guidelines because they seek a more personalised approach&#44; which certainly reflects the phenotypic diversity of the patients seen in clinical practice&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Vascular risk assessment</span><p id="par0015" class="elsevierStylePara elsevierViewall">The new guidelines on cardiovascular prevention recommend systematically calculating vascular risk &#40;VR&#41; in all adults with any VR factor&#44; which could also be in men&#62;40 years and women&#62;50 years&#44; and repeated every 5 years&#46; Some publications<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> have highlighted potential risks of labelling people as low VR&#44; as they may be given a false sense of security that they are protected from vascular disease&#44; which might compromise their motivation to prevent risk factors&#46; Most of the population fall into these risk bands &#40;moderate or low&#41;&#44; where more cases of vascular disease occur in absolute numbers&#46; Therefore&#44; it is essential to promote health lifestyles in the entire population&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">The therapeutic targets for low-density lipoprotein cholesterol &#40;LDL-C&#41;&#44; blood pressure &#40;BP&#41;&#44; and blood glucose have not changed from the previous guidelines&#44; but the way they are controlled in individuals has been modified in a stepwise manner &#40;steps 1 and 2&#41;&#46; This approach is not new as a concept&#44; and is intended to reflect the usual clinical practice of the progressive intensification of therapeutic strategies as part of a shared decision-making process between healthcare professionals and patients&#46; It is always recommended to get to step 2&#44; and treatment will be intensified according to 10-year and lifetime risk&#44; treatment benefit&#44; comorbidities&#44; frailty&#44; and patient preferences&#46; However&#44; we should not forget that according to the results of the EUROASPIRE study&#44;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> conducted in 27 European countries&#44; we are still a long way from achieving therapeutic objectives &#40;71&#37; of people with coronary heart disease had LDL-C&#8805;70&#8239;mg&#47;dl&#41;&#44; and this stepwise strategy could encourage inertia&#44; compromising the earliest possible achievement of objectives&#44; especially in patients with high or very high CVR&#46; Therefore&#44; in patients at high or very high VR&#44; particularly those who have already experienced a vascular event&#44; we continue to recommend strict achievement of LDL-C targets along with the &#8805;50&#37; reduction in LDL-C from baseline in a single step and as soon as possible&#46; Regardless of risk&#44; smoking cessation&#44; adopting a healthy lifestyle and a systolic blood pressure &#40;SBP&#41;&#60;160&#8239;mmHg are recommended for all individuals&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">For the first time&#44; the guidelines present a new model for calculating risk &#8211; SCORE2<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> and SCORE2-OP<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> &#8211; which has been calibrated for 4 European regions according to vascular mortality rates&#59; Spain is one of the low VR countries&#46; This tool allows calculation of the risk of vascular morbidity and mortality in the next 10 years &#40;myocardial infarction&#44; stroke&#44; and vascular mortality&#41; in men and women between 40 and 89 years of age&#46; The coloured tables in the guidelines &#40;using SBP&#44; age&#44; sex&#44; smoking&#44; and non-high-density lipoprotein cholesterol&#41; can be used&#44; the European Society of Cardiology App or the tool available on the web &#40;<a href="https://u-prevent.com">https&#58;&#47;&#47;u-prevent&#46;com</a>&#41;&#44; where total and high-density lipoprotein cholesterol can be entered&#46; These applications can also be used to calculate lifetime VR &#40;LIFE-CV model&#41; and the benefits of treatment in terms of years of life gained without vascular disease&#46; In addition&#44; there are specific tools for risk calculation in people with diabetes &#40;ADVANCE risk score or DIAL model&#41; and with established vascular disease &#40;SMART REACH score or SMART REACH model&#41;&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Vascular risk categories according to SCORE2&#47;SCORE2-OP in apparently healthy people</span><p id="par0030" class="elsevierStylePara elsevierViewall">Another substantial development is the establishment of different risk thresholds according to age&#44; as shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#44; in contrast to previous versions&#44; which established a single risk threshold&#44; to avoid undertreatment in young people and overtreatment in older people&#44; as the long-term benefit of treating VR factors is greater in younger patients&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">It is recommended that all very high-risk individuals should be treated&#44; and treatment should be considered for those at high risk&#44; based on risk modifiers&#44; lifetime risk&#44; treatment benefits and personal preferences&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">The VR calculation and treatment algorithms for VR factors for apparently healthy individuals&#44; patients with atherosclerotic vascular disease and patients with diabetes are presented in <a class="elsevierStyleCrossRefs" href="#fig0005">Figs&#46; 1&#8211;3</a>&#46; Patients with chronic kidney disease &#40;CKD&#41; will be considered high or very high risk based on glomerular filtration rate and albumin&#47;creatinine ratio &#40;ACR&#41;&#46; Patients with familial hypercholesterolaemia are considered high risk&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0045" class="elsevierStylePara elsevierViewall">The importance of communication with the patient is emphasised and an informed discussion of risk and therapeutic benefits&#44; tailored to the needs of the individual&#44; is recommended&#46; In particular&#44; the need for lifelong VR use is mentioned&#44; especially in younger individuals&#44; and the lifelong benefits after intervention or vascular age&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Risk modifiers</span><p id="par0050" class="elsevierStylePara elsevierViewall">Few risk modifiers meet the criteria to be considered in the VR calculation&#58; to improve prediction &#40;discrimination and reclassification&#41;&#44; to have a clear public health impact &#40;number of patients to be treated or screened&#41; and to be feasible for implementation in clinical practice&#46; The most relevant modifiers are summarised in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Developments in lifestyle recommendations</span><p id="par0055" class="elsevierStylePara elsevierViewall">The CEIPV has adapted the recommendations of the new guidelines based on those of the World Health Organisation and the Ministry of Health&#46; They recommend&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">none-</span><p id="par0060" class="elsevierStylePara elsevierViewall">Engaging in at least 150&#8722;300&#8239;min of moderate physical activity per week &#40;or 75&#8722;150&#8239;min of vigorous activity or an equivalent combination of both&#41; and performing muscle strengthening&#44; bone mass improvement&#44; and flexibility activities at least 2 days per week&#46;<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9&#44;10</span></a></p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">none-</span><p id="par0065" class="elsevierStylePara elsevierViewall">Reducing sedentary periods&#44; with breaks for activity every 1&#8239;h or 2&#8239;h&#44; increasing active transport and limiting screen time&#46;<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9&#44;10</span></a></p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">none-</span><p id="par0070" class="elsevierStylePara elsevierViewall">Eating a healthy and sustainable diet based on fresh&#44; seasonal&#44; and local foods&#58; including at least 5 portions of fruit and vegetables a day&#44; wholegrain cereals&#44; prioritise vegetable protein &#40;pulses&#44; nuts&#41; and fish&#44; preferably oily fish&#44; incorporating eggs&#44; chicken&#44; natural yoghurt&#44; and milk in moderation&#44; and avoiding red or processed meat&#44; convenience foods&#44; industrial pastries&#44; and sugary drinks&#46;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a></p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">none-</span><p id="par0075" class="elsevierStylePara elsevierViewall">Avoiding alcohol&#44; as this is the only recommendation that avoids the risks associated with alcohol consumption&#46; If consumed&#44; the less the better&#44; and always below the low-risk consumption limits&#58; 10&#8239;g alcohol&#47;day &#40;one standard drink unit&#41; in women and 20&#8239;g&#47;day &#40;2 standard drink units&#41; in men&#44;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> leaving a few days a week alcohol free and avoiding binge drinking&#59; consumption should be completely avoided in children under 18 years of age and during pregnancy and breastfeeding&#46;</p></li></ul></p><p id="par0080" class="elsevierStylePara elsevierViewall">Cessation of tobacco use in all its forms&#44; including tobacco products and related products such as e-cigarettes&#44; and avoid of environmental exposure to tobacco smoke&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Developments in the treatment of risk factors in patients with vascular disease</span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Lipids</span><p id="par0085" class="elsevierStylePara elsevierViewall">A stepwise approach to intensifying treatment is advised in otherwise healthy individuals with high or very high VR and in patients with vascular disease or diabetes&#44; considering VR&#44; treatment benefit&#44; risk modifiers&#44; co-morbidities&#44; and personal preferences&#46; In patients who have had vascular disease&#44; in order to reach therapeutic LDL-C targets as soon as possible&#44; it is recommended to proceed directly to step 2 &#40;see section on VR&#41;&#46; High-intensity statins are recommended in people at very high risk or with vascular disease&#44; and if LDL-C targets are not achieved&#44; ezetimibe should be added&#44; and if targets are still not achieved&#44; a PCSK9 inhibitor should be added&#46; Although this recommendation agrees with meeting targets in 2 steps&#44; it is difficult to achieve reductions&#8805;50&#37; in LDL-C&#44; unless with maximal doses of atorvastatin and rosuvastatin&#46; The available evidence suggests changing the terminology of &#8220;high-potency statins&#8221; to &#8220;high-intensity cholesterol-lowering therapy&#8221;&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> Thus&#44; the first option in patients with high or very high VR could be to use non-maximal doses of statins &#40;atorvastatin 40&#8239;mg or rosuvastatin 10&#8239;mg&#41; associated with ezetimibe&#44; which help therapeutic goals to be met with better tolerance and adherence&#46; The addition of n-3 fatty acids &#40;ethyl icosapentate 2&#8239;&#215;&#8239;2&#8239;g&#47;day&#41; to statin therapy could be considered in high or very high-risk patients with mild&#47;moderate hypertriglyceridaemia &#40;triglyceride levels above 150&#8239;mg&#47;dl&#41;&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Hypertension</span><p id="par0090" class="elsevierStylePara elsevierViewall">In contrast to the American guidelines &#40;ACC&#47;AHA 2017&#41;&#44; the same classical threshold is still recommended to define hypertension &#40;HTN&#41;&#44; classifying it as optimal BP&#44; normal BP&#44; normal-high BP&#44; and HT grades 1&#8211;3 &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#41;&#46; The Spanish Society of Hypertension-Spanish League for Combating High Blood Pressure has already published a position paper justifying the desirability of maintaining this same cut-off point to define HTN&#46;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0095" class="elsevierStylePara elsevierViewall">It is recommended to initiate treatment in individuals with grade 1 HTN considering VR&#44; lifetime benefit&#44; and the presence of target organ involvement&#46; However&#44; despite evidence of the benefit of lowering BP in reducing vascular morbidity and mortality&#44; BP monitoring in Europe and other parts of the world is suboptimal&#44; especially in low- and middle-income countries&#44;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> and has worsened in recent years&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> Although the cause is multifactorial&#44; poor adherence plays an important role&#46; The recommended strategy for initial treatment remains the use of drug combinations&#44; with an angiotensin-converting enzyme inhibitor or an angiotensin II receptor antagonist in combination with a thiazide diuretic or a long half-life calcium antagonist &#40;<a class="elsevierStyleCrossRef" href="#fig0020">Fig&#46; 4</a>&#41;&#46; A recent meta-analysis has shown that this strategy improves adherence and control rate in patients with HTN&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a></p><elsevierMultimedia ident="fig0020"></elsevierMultimedia></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Diabetes mellitus</span><p id="par0100" class="elsevierStylePara elsevierViewall">Metformin is recommended as first-line treatment of diabetes mellitus &#40;DM&#41; with monitoring of renal function&#44; especially in patients without vascular disease&#44; chronic renal failure&#44; or heart failure&#46; In these cases&#44; in addition to the use or non-use of metformin&#44; treatment with glucagon-like peptide receptor agonists type 1 or sodium-glucose cotransporter inhibitors type 2 that have demonstrated a reduction in vascular and renal events is recommended&#46; In patients with DM and CKD&#44; sodium-glucose cotransporter type 2 inhibitors are recommended due to their vascular and renal benefits&#46; In patients with DM and reduced ejection fraction&#44; sodium-glucose cotransporter type 2 inhibitors are recommended to reduce hospitalisation for heart failure and vascular deaths&#46;</p><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Chronic kidney disease</span><p id="par0105" class="elsevierStylePara elsevierViewall">CKD&#44; as defined by estimated glomerular filtration rate &#40;eGFR&#41; and urine ACR&#44; determines prognosis &#40;<a class="elsevierStyleCrossRef" href="#fig0025">Fig&#46; 5</a>&#41;&#46; In patients without DM&#44; an eGFR&#60;30&#8239;ml&#47;min&#47;1&#46;73&#8239;m<span class="elsevierStyleSup">2</span> or an eGFR 30&#8722;44&#8239;ml&#47;min&#47;1&#46;73&#8239;m<span class="elsevierStyleSup">2</span> with an ACR&#62;30&#8239;mg&#47;g determines a very high risk of vascular events&#44; in the same way as a previous vascular event&#46; On the other hand&#44; an eGFR of 30&#8722;44&#8239;ml&#47;min&#47;1&#46;73&#8239;m<span class="elsevierStyleSup">2</span> and an ACR&#60;30&#8239;mg&#47;g or an eGFR of 45&#8722;59&#8239;ml&#47;min&#47;1&#46; 73&#8239;m<span class="elsevierStyleSup">2</span> and an ACR of 30&#8722;300&#8239;mg&#47;g&#44; or an eGFR&#8805;60&#8239;ml&#47;min&#47;1&#46;73&#8239;m<span class="elsevierStyleSup">2</span> and an ACR&#62;300&#8239;mg&#47;g determines an elevated risk of vascular events&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> In patients with DM&#44; severe target organ damage is considered to be an eFGR&#60;45&#8239;ml&#47;min&#47;1&#46;73&#8239;m<span class="elsevierStyleSup">2</span>&#44; or an eGFR of 45&#8722;59&#8239;ml&#47;min&#47;1&#46;73&#8239;m<span class="elsevierStyleSup">2</span> and an ACR of 30&#8722;300&#8239;mg&#47;g&#44; or an ACR&#62;300&#8239;mg&#47;g&#59; similarly&#44; the presence of microvascular complications in 3 different sites confers a very high VR&#46; In patients with CKD&#44; general smoking cessation and improved lifestyle measures&#44; SBP control targets between 130 and 140&#8239;mmHg and DBP&#60;80&#8239;mmHg according to tolerance&#44; and LDL-C targets less than 70&#8239;mg&#47;dl or 55&#8239;mg&#47;dl in patients with high or very high VR are recommended&#46; In patients with DM and diabetic kidney disease&#44; the use of hypoglycaemic drugs with recognised renal protective effects is recommended&#46;</p><elsevierMultimedia ident="fig0025"></elsevierMultimedia></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Antithrombotic therapy</span><p id="par0110" class="elsevierStylePara elsevierViewall">The addition of a second antithrombotic drug &#40;P2Y12 platelet receptor inhibitor or low-dose rivaroxaban&#41; to aspirin should be considered for secondary prevention of vascular disease in patients at high ischaemic and low haemorrhagic risk&#46; Combination therapy with aspirin and low-dose rivaroxaban could be considered in patients with diabetes and peripheral arterial disease&#46; Treatment with low-dose colchicine &#40;&#46;5&#8239;mg&#47;day&#41; could be considered in secondary prevention of vascular disease if other VR factors are inadequately controlled or in the case of recurrent ischaemic events despite optimal treatment&#46;</p></span></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Population-based prevention strategies</span><p id="par0115" class="elsevierStylePara elsevierViewall">Much greater emphasis is placed on health policy as a population-based prevention strategy&#46; The aim is to reduce the attributable risk of risk factors&#44; i&#46;e&#46;&#44; the burden of vascular disease that can be prevented by eliminating or reducing the prevalence of each factor&#46; These strategies are based on Geoffrey Rose&#8217;s Prevention Paradox&#44; according to which small shifts in the population distribution of risk factors to the left have a large impact on the overall burden of disease&#46;<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> Guidelines and other recommendations from international bodies such as the World Health Organisation<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20&#8211;23</span></a> propose the most cost-effective population-based interventions to create environments that promote healthy lifestyles by modifying risk factors such as physical inactivity&#44; unhealthy diet&#44; tobacco&#44; and alcohol consumption&#44;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> exposure to air and noise pollution<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> &#40;especially from road traffic&#41;&#44; and by acting on climate change&#46; In addition&#44; different methods &#40;governmental&#44; media and education&#44; labelling and information&#44; financial incentives&#41;&#44; settings &#40;schools&#44; workplace&#44; community&#41; and actions are described for each of them&#44; supported with a level of evidence and a class of recommendation&#46; The goal&#44; and the task for national&#44; regional&#44; and local authorities&#44; is to make a healthy lifestyle easy&#44; creating environments where the default choices are health-promoting&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Recommendations for promoting physical activity and reducing sedentary lifestyles include urban planning measures to facilitate active and healthy mobility&#44; active transport and increasing the availability of spaces and equipment that encourage physical activity in schools and community settings&#46; To promote healthy eating&#44; legislative measures are included to ban or reduce trans fats&#44; reduce calorie intake&#44; salt&#44; added sugars and saturated fats in prepared foods and beverages&#44; fiscal measures &#40;taxation or incentives&#41; on some foods and beverages&#44; and availability of healthy meals on menus and in food vending machines in schools and workplaces&#46; Recommendations&#44; mainly legislative&#44; are also included to reduce tobacco and alcohol consumption&#58; regulation of consumption in public places&#44; availability and sale&#44; advertising&#44; labelling and packaging&#44; pricing policies&#44; and the implementation of educational campaigns&#46;<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">21&#8211;26</span></a> Finally&#44; measures are recommended to reduce emissions of small particles and gaseous pollutants&#44; the use of solid fuels and road traffic&#44; and to limit carbon dioxide emissions to reduce CV morbidity and mortality&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">The population-based approach offers many benefits&#44; such as reducing the gap in health inequalities&#44; preventing other non-communicable diseases that have common risk factors and determinants with vascular events&#44; such as cancer&#44; lung disease&#44; and type 2 DM&#44; and saving the health and social costs of vascular events that have been prevented&#46;</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Conflict of interests</span><p id="par0130" class="elsevierStylePara elsevierViewall">The authors have no conflict of interests to declare&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:14 [
        0 => array:3 [
          "identificador" => "xres2021537"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1730595"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres2021536"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1730596"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Vascular risk assessment"
        ]
        6 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Vascular risk categories according to SCORE2&#47;SCORE2-OP in apparently healthy people"
        ]
        7 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Risk modifiers"
        ]
        8 => array:2 [
          "identificador" => "sec0025"
          "titulo" => "Developments in lifestyle recommendations"
        ]
        9 => array:3 [
          "identificador" => "sec0030"
          "titulo" => "Developments in the treatment of risk factors in patients with vascular disease"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Lipids"
            ]
            1 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Hypertension"
            ]
          ]
        ]
        10 => array:3 [
          "identificador" => "sec0045"
          "titulo" => "Diabetes mellitus"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Chronic kidney disease"
            ]
            1 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Antithrombotic therapy"
            ]
          ]
        ]
        11 => array:2 [
          "identificador" => "sec0060"
          "titulo" => "Population-based prevention strategies"
        ]
        12 => array:2 [
          "identificador" => "sec0065"
          "titulo" => "Conflict of interests"
        ]
        13 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-03-21"
    "fechaAceptado" => "2022-03-28"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1730595"
          "palabras" => array:9 [
            0 => "Prevention and control"
            1 => "Vascular diseases"
            2 => "Clinical Practice Guidelines"
            3 => "Healthy diet"
            4 => "Arterial hypertension"
            5 => "Diabetes"
            6 => "Lipid control"
            7 => "Smoking"
            8 => "Cardiovascular risk"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1730596"
          "palabras" => array:9 [
            0 => "Prevenci&#243;n y control"
            1 => "Enfermedades vasculares"
            2 => "Gu&#237;as de Pr&#225;ctica Cl&#237;nicas"
            3 => "Dieta saludable"
            4 => "Hipertensi&#243;n arterial"
            5 => "Diabetes"
            6 => "Control de l&#237;pidos"
            7 => "Tabaco"
            8 => "Riesgo cardiovascular"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease &#40;CVD&#41; prevention in clinical practice&#46; The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases&#46; Systematic global CVD risk assessment is recommended in individuals with any major vascular risk factor&#46; Regarding LDL-Cholesterol&#44; blood pressure&#44; and glycemic control in patients with diabetes mellitus&#44; goals and targets remain as recommended in previous guidelines&#46; However&#44; it is proposed a new&#44; stepwise approach &#40;Step 1 and 2&#41; to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile&#46; After Step 1&#44; considering proceeding to the intensified goals of Step 2 is mandatory&#44; and this intensification will be based on 10-year CVD risk&#44; lifetime CVD risk and treatment benefit&#44; comorbidities and patient preferences&#46;</p><p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">The updated SCORE algorithm&#8212;SCORE2&#44; SCORE-OP&#8212; is recommended in these guidelines&#44; which estimates an individual&#8217;s 10-year risk of fatal and non-fatal CVD events &#40;myocardial infarction&#44; stroke&#41; in healthy men and women aged 40&#8211;89 years&#46; Another new and important recommendation is the use of different categories of risk according different age groups &#40;&#60;50&#44; 50&#8722;69&#44; &#8805;70 years&#41;&#46;</p><p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Different flow charts of CVD risk and risk factor treatment in apparently healthy persons&#44; in patients with established atherosclerotic CVD&#44; and in diabetic patients are recommended&#46; Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio&#46; New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids&#44; blood pressure&#44; diabetes and chronic renal failure are included&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Presentamos la adaptaci&#243;n espa&#241;ola de las Gu&#237;as Europeas de Prevenci&#243;n Cardiovascular 2021&#46; En esta actualizaci&#243;n adem&#225;s del abordaje individual&#44; se pone mucho m&#225;s &#233;nfasis en las pol&#237;ticas sanitarias como estrategia de prevenci&#243;n poblacional&#46; Se recomienda el c&#225;lculo del riesgo vascular de manera sistem&#225;tica a todas las personas adultas con alg&#250;n factor de riesgo vascular&#46; Los objetivos terap&#233;uticos para el colesterol LDL&#44; la presi&#243;n arterial y la glucemia no han cambiado respecto a las anteriores gu&#237;as&#44; pero se recomienda alcanzar estos objetivos de forma escalonada &#40;etapas 1 y 2&#41;&#46; Se recomienda llegar siempre hasta la etapa 2&#44; y la intensificaci&#243;n del tratamiento depender&#225; del riesgo a los 10 a&#241;os y de por vida&#44; del beneficio del tratamiento&#44; de las comorbilidades&#44; de la fragilidad y de las preferencias de los pacientes&#46; Las gu&#237;as presentan por primera vez un nuevo modelo para calcular el riesgo -SCORE2 y SCORE2-OP de morbimortalidad vascular en los pr&#243;ximos 10 a&#241;os &#40;infarto de miocardio&#44; ictus y mortalidad vascular&#41; en hombres y mujeres entre 40 y 89 a&#241;os&#46; Otra de las novedades sustanciales es el establecimiento de diferentes umbrales de riesgo dependiendo de la edad &#40;&#60;50&#44; 50&#8722;69&#44; &#8805;70 a&#241;os&#41;&#46;</p><p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">Se presentan diferentes algoritmos de c&#225;lculo del riesgo vascular y tratamiento de los factores de riesgo vascular para personas aparentemente sanas&#44; pacientes con diabetes y pacientes con enfermedad vascular ateroscler&#243;tica&#46; Los pacientes con enfermedad renal cr&#243;nica se considerar&#225;n de riesgo alto o muy alto seg&#250;n la tasa del filtrado glomerular y el cociente alb&#250;mina&#47;creatinina&#46; Se incluyen innovaciones en las recomendaciones sobre los estilos de vida&#44; adaptadas a las recomendaciones del Ministerio de Sanidad&#44; as&#237; como aspectos novedosos relacionados con el control de los l&#237;pidos&#44; la presi&#243;n arterial&#44; la diabetes y la insuficiencia renal cr&#243;nica&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Please cite this article as&#58; Brotons C&#44; Camafort M&#44; Castellanos MdM&#44; Clar&#224; A&#44; Cort&#233;s O&#44; Diaz Rodriguez A&#44; et al&#46; Comentario del CEIPV a las nuevas Gu&#237;as Europeas de Prevenci&#243;n Cardiovascular 2021&#46; Clin Investig Arterioscl&#46; 2022&#59;73&#58;219&#8211;228&#46;</p>"
      ]
    ]
    "multimedia" => array:8 [
      0 => array:9 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "fuente" => "Adapted from Figure 6&#44; page 26&#46; Eur Heart J&#46; 2021&#59;42&#58;3227&#8722;3337&#46; doi&#58; <span class="elsevierStyleInterRef" id="intr0005" href="https://doi.org/10.1093/eurheartj/ehab484">https&#58;&#47;&#47;doi&#46;org&#47;10&#46;1093&#47;eurheartj&#47;ehab484</span>&#46;"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 4151
            "Ancho" => 2925
            "Tamanyo" => 934541
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Vascular risk algorithm and therapeutic targets in apparently healthy patients&#46; LDL-C&#44; low-density lipoprotein cholesterol&#59; CV&#44; cardiovascular&#59; CVD&#44; cardiovascular disease&#59; SBP&#44; systolic blood pressure&#59; SCORE2&#44; Systematic Coronary Risk Estimation 2&#59; SCORE2-OP&#44; Systematic Coronary Risk Estimation 2-Older Persons&#46;</p>"
        ]
      ]
      1 => array:9 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "fuente" => "Adapted from Figure 7&#44; page 27&#44; Eur Heart J&#46; 2021&#59;42&#58;3227&#8722;3337&#46; doi&#58; <span class="elsevierStyleInterRef" id="intr0010" href="https://doi.org/10.1093/eurheartj/ehab484">https&#58;&#47;&#47;doi&#46;org&#47;10&#46;1093&#47;eurheartj&#47;ehab484</span>&#46;"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 2621
            "Ancho" => 2508
            "Tamanyo" => 431388
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0010"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Therapeutic target and pharmacological treatment algorithm in patients with established vascular disease&#46; LDL-C&#58; Low density lipoprotein cholesterol&#59; CV&#58; cardiovascular&#59; DAPT&#58; dual antiplatelet therapy&#59; DPI&#58; dual pathway inhibition&#59; CVD&#58; cardiovascular disease&#59; SBP&#58; systolic blood pressure&#46;</p>"
        ]
      ]
      2 => array:9 [
        "identificador" => "fig0015"
        "etiqueta" => "Figure 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "fuente" => "Adapted from Figure 8&#44; page 29&#44; Eur Heart J&#46; 2021&#59;42&#58;3227&#8722;3337&#46; doi&#58; <span class="elsevierStyleInterRef" id="intr0015" href="https://doi.org/10.1093/eurheartj/ehab484">https&#58;&#47;&#47;doi&#46;org&#47;10&#46;1093&#47;eurheartj&#47;ehab484</span>&#46;"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 4181
            "Ancho" => 2925
            "Tamanyo" => 915187
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0015"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Vascular risk algorithm&#44; therapeutic objectives&#44; and pharmacological treatment in patients with diabetes&#46; CVD&#58; cardiovascular disease&#59; DAPT&#58; dual antiplatelet therapy&#59; DPI&#58; dual pathway inhibition&#59; GLP-1RA&#58; glucagon-like peptide-1 receptor agonists&#59; HbAIc&#58; glycosylated haemoglobin&#59; LDL-C&#58; low-density lipoprotein cholesterol&#59; SBP&#58; systolic blood pressure&#59; SGLT2-i&#58; sodium&#47;glucose cotransporter-2 inhibitors&#59; TOD&#58; target organ damage&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig0020"
        "etiqueta" => "Figure 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 859
            "Ancho" => 2175
            "Tamanyo" => 204294
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0020"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Strategy to treat hypertension &#40;HTN&#41; without associated clinical complications&#46; ACE inhibitor&#58; angiotensin-converting enzyme inhibitor&#59; AF&#58; atrial fibrillation&#59; ARA II&#58; Angiotensin II receptor antagonists&#59; BB&#58; betablocker&#59; CCB&#58; calcium channel blocker&#59; CHD&#58; coronary heart disease&#59; comp&#58; compromised&#59; HF&#58; heart failure&#59; SBP&#58; systolic blood pressure&#46;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "fig0025"
        "etiqueta" => "Figure 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr5.jpeg"
            "Alto" => 1080
            "Ancho" => 2175
            "Tamanyo" => 219853
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0025"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Chronic kidney disease related risk according to glomerular filtration rate and albuminuria categories&#46; Areas in green&#58; reference risk &#40;no kidney disease if no other defining markers are present&#41;&#59; areas in yellow&#58; moderate risk&#59; areas in orange&#58; high risk&#59; areas in red&#58; very high risk&#46;</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">&#42;Albuminuria is expressed as albumin-creatinine ratio&#46;</p> <p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Guidelines Kidney Disease&#58; Improving Global Outcomes &#8210;KDIGO&#8210; on chronic kidney disease&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0030"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Risk in the next 10 years&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#60;50 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">50&#8722;69 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#8805;70 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Low to moderate vascular risk&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;2&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;7&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">High vascular risk&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;5 a&#60;7&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 a&#60;10&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#46;5 a&#60;15&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Very high vascular risk&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8805;7&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8805;10&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8805;15&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3354862.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Vascular risk categories according to age group&#46;</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0035"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">BMI&#58; body mass index&#59; CV&#58; cardiovascular&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Psychosocial factors&#58; psychosocial stress is associated with increased vascular risk Ethnicity&#58; in South Asian population&#44; multiply the risk by 1&#46;1&#8722;1&#46;7&#44; in Black Caribbean or African population&#44; multiply by &#46;85&#44; and in Chinese population&#44; multiply by &#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Imaging tests&#58; coronary calcium or&#44; if not&#44; presence of carotid plaque&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Family history of premature CV disease&#58; although this only marginally improves risk prediction&#44; it is simple and easy to measure&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Frailty&#58; frailty has been shown to have an independent relationship with vascular risk&#44; but it is not recommended to be considered in risk calculation&#46; Caution is recommended with pharmacological interventions&#44; due to potential side effects of drug interactions&#44; and with implantation of devices&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Socioeconomic status&#58; lower socioeconomic class is associated with higher vascular risk&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Environmental pollution&#58; it is recommended that patients at high or very high risk of vascular disease try to avoid prolonged exposure to high pollution&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Body composition&#58; BMI&#44; waist circumference and waist-to-hip ratio have been independently associated with vascular disease&#44; although there is no evidence that they improve reclassification&#46; However&#44; they are simple and easy to measure&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3354861.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Risk modifiers&#46;</p>"
        ]
      ]
      7 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0040"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">BP for classification will be based on the mean of 2 or more readings&#44; on 2 or more occasions&#44; following standardised recommendations for quality measures&#46; Subjects with systolic blood pressure &#40;SBP&#41; and diastolic blood pressure &#40;DBP&#41; in different categories will be classified in the highest category&#46;</p><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Current guidelines on the diagnosis and treatment of hypertension &#40;HTN&#41; indicate the need to determine ambulatory BP levels by ambulatory blood pressure monitoring or self-measurement of blood pressure&#44; given the high prevalence of white-coat and masked HTN&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">BP category<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">SBP &#40;mmHg&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">DBP &#40;mmHg&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Optimal BP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;120&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">and&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;80&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Normal BP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">120&#8722;129&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">or&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">80&#8722;84&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Normal-high BP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">130&#8722;139&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">or&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">85&#8722;89&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Grade 1 HTN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">140&#8722;159&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">or&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">90&#8722;99&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Grade 2 HTN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">160&#8722;179&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">or&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100&#8722;109&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Grade 3 HTN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8805;180&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">or&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8805;110&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Isolated systolic HTN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8805;140&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">and&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;90&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3354860.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Definitions are based on blood pressure &#40;BP&#41; measured seated in the consultation&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Classification of clinical BP &#40;in consultation&#41; according to clinical BP values&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:26 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "ESC Scientific Document Group&#44; 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice&#58; Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology &#40;EAPC&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46;L&#46;J&#46; Visseren"
                            1 => "F&#46; Mach"
                            2 => "Y&#46;M&#46; Smulders"
                            3 => "D&#46; Carballo"
                            4 => "K&#46;C&#46; Koskinas"
                            5 => "M&#46; B&#228;ck"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehab484"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2021"
                        "volumen" => "42"
                        "paginaInicial" => "3227"
                        "paginaFinal" => "3337"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34458905"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2016 European guideliness on cardiovascular disease prevention in clinical practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;F&#46; Piepoli"
                            1 => "A&#46;W&#46; Hoes"
                            2 => "S&#46; Agewall"
                            3 => "C&#46; Albus"
                            4 => "C&#46; Brotons"
                            5 => "A&#46;L&#46; Catapano"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehw106"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2016"
                        "volumen" => "37"
                        "paginaInicial" => "2315"
                        "paginaFinal" => "2381"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27222591"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Update on cardiovascular prevention in clinical practice&#58; a position paper of the European Association of Preventive Cardiology of the European Society of Cardiology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;F&#46; Piepoli"
                            1 => "A&#46; Abreu"
                            2 => "C&#46; Albus"
                            3 => "M&#46; Ambrosetti"
                            4 => "C&#46; Brotons"
                            5 => "A&#46;L&#46; Catapano"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Eur J Prev Cardiol"
                        "fecha" => "2020"
                        "volumen" => "27"
                        "paginaInicial" => "181"
                        "paginaFinal" => "205"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comentario del CEIPV a la actualizaci&#243;n de las Gu&#237;as Europeas de Prevenci&#243;n Vascular en la Pr&#225;ctica Cl&#237;nica"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Armario"
                            1 => "C&#46; Brotons"
                            2 => "R&#46; Elosua"
                            3 => "M&#46; Alonso de Leci&#241;ana"
                            4 => "A&#46; Castro"
                            5 => "A&#46; Clar&#224;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Rev Esp Salud P&#250;blica"
                        "fecha" => "2020"
                        "volumen" => "94"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "on behalf of the Stroke Experts Collaboration Group Primary stroke prevention worldwide&#58; translating evidence into action"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;O&#46; Owolabi"
                            1 => "A&#46;G&#46; Thrif"
                            2 => "A&#46; Mahal"
                            3 => "M&#46; Ishida"
                            4 => "S&#46; Martin"
                            5 => "W&#46;D&#46; Johnson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S2468-2667(21)00230-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Public Health"
                        "fecha" => "2022"
                        "volumen" => "7"
                        "paginaInicial" => "e74"
                        "paginaFinal" => "85"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34756176"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EUROASPIRE V collaborators&#59; Writing Committee&#59; Scientific Steering&#47;Executive Committee&#59; Coordinating centre&#59; Diabetes centre&#59; Data management centre&#59; Statistical analysis centre&#59; Central laboratory&#59; Study centres&#44; organisations&#44; investigators and other research personnel &#40;National Coordinators in each country are indicated by asterisk&#46; Management of dyslipidaemia in patients with coronary heart disease&#58; results from the ESC-EORP EUROASPIRE V survey in 27 countries"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; De Backer"
                            1 => "P&#46; Jankowski"
                            2 => "K&#46; Kotseva"
                            3 => "E&#46; Mirrakhimov"
                            4 => "&#381; Reiner"
                            5 => "L&#46; Ryd&#233;n"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.atherosclerosis.2019.03.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "Atherosclerosis"
                        "fecha" => "2019"
                        "volumen" => "285"
                        "paginaInicial" => "135"
                        "paginaFinal" => "146"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31054483"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "SCORE2 risk prediction algorithms&#58; new models to estimate 10-year risk of cardiovascular disease in Europe"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "SCORE2 working group and ESC Cardiovascular risk collaboration"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehab309"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2021"
                        "volumen" => "42"
                        "paginaInicial" => "2439"
                        "paginaFinal" => "2454"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34120177"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "SCORE2-OP risk prediction algorithms&#58; estimating incident cardiovascular event risk in older persons in four geographical risk regions"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "SCORE2-OP working group and ESC Cardiovascular risk collaboration&#46;"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehab312"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2021"
                        "volumen" => "42"
                        "paginaInicial" => "2455"
                        "paginaFinal" => "2467"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34120185"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Directrices de la OMSsobre actividad f&#237;sica y h&#225;bitos sedentarios"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Organizaci&#243;n Mundial de la Salud"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "WWW" => array:2 [
                        "link" => "https&#58;&#47;&#47;apps&#46;who&#46;int&#47;iris&#47;bitstream&#47;handle&#47;10665&#47;337004&#47;9789240014817-spa&#46;pdf"
                        "fecha" => "2020"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ministerio de Sanidad&#46; Recomendaciones para lapoblaci&#243;n sobre actividad f&#237;sica y reducci&#243;n del seden-tarismo&#46; Madrid&#58; Ministerio de Sanidad&#46; Available from&#58; <a target="_blank" href="https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/Estrategia/Recomendaciones_ActivFisica.htm">https&#58;&#47;&#47;www&#46;sanidad&#46;gob&#46;es&#47;profesionales&#47;saludPublica&#47;prevPromocion&#47;Estrategia&#47;Recomendaciones&#95;ActivFisica&#46;htm</a>&#46;"
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Dietary and policy priorities for cardiovascular disease&#44; diabetes&#44; and obesity&#58; a comprehensive review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "D&#46; Mozaffarian"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/CIRCULATIONAHA.115.018585"
                      "Revista" => array:6 [
                        "tituloSerie" => "Circulation"
                        "fecha" => "2016"
                        "volumen" => "133"
                        "paginaInicial" => "187"
                        "paginaFinal" => "225"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26746178"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "L&#237;mites de Consumo de Bajo Riesgo de Alcohol&#46; Actualizaci&#243;n del riesgo relacionado con los niveles de consumo de alcohol&#44; el patr&#243;n de consumo y el tipo de bebida"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Ministerio de Sanidad"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "WWW" => array:2 [
                        "link" => "https&#58;&#47;&#47;www&#46;sanidad&#46;gob&#46;es&#47;profesionales&#47;saludPublica&#47;prevPromocion&#47;Prevencion&#47;alcohol&#47;Limites&#95;Consumo&#95;Bajo&#95;Riesgo&#95;Alcohol&#46;htm"
                        "fecha" => "2021"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "IMPROVE-IT clinicalimplications&#46; Should the &#8220;high-intensity cholesterol-lowering therapy&#8221; strategy replace the &#8220;high-intensity statin therapy&#8221;&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "L&#46; Masana"
                            1 => "J&#46; Pedro-Botet"
                            2 => "F&#46; Civeira"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.atherosclerosis.2015.03.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Atherosclerosis"
                        "fecha" => "2015"
                        "volumen" => "240"
                        "paginaInicial" => "161"
                        "paginaFinal" => "162"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25795557"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Documento de la Sociedad Espa&#241;ola de Hipertensi&#243;n-Liga Espa&#241;ola para la Lucha contra la Hipertensi&#243;n Arterial &#40;SEH-LELHA&#41; sobre las gu&#237;as ACC&#47;AHA 2017 de hipertensi&#243;n arterial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Gij&#243;n-Conde"
                            1 => "M&#46; Gorostidi"
                            2 => "M&#46; Camafort"
                            3 => "M&#46; Abad-Cardiel"
                            4 => "E&#46; Martin-Rioboo"
                            5 => "F&#46; Morales-Oliva"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Hipertens Riesgo Vasc"
                        "fecha" => "2018"
                        "volumen" => "35"
                        "paginaInicial" => "119"
                        "paginaFinal" => "129"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hypertension pharmacological treatment in adults&#58; a World Health Organization Guideline Executive Summary"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Al-Makki"
                            1 => "D&#46; DiPette"
                            2 => "P&#46;K&#46; Whelton"
                            3 => "M&#46;H&#46; Murad"
                            4 => "R&#46;A&#46; Mustafa"
                            5 => "S&#46; Acharya"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/HYPERTENSIONAHA.121.18192"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hypertension"
                        "fecha" => "2022"
                        "volumen" => "79"
                        "paginaInicial" => "293"
                        "paginaFinal" => "301"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34775787"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Medication adherence and blood pressure control&#58; a scientific statement from the American Heart Association"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "N&#46;K&#46; Choudrhy"
                            1 => "I&#46;M&#46; Kronish"
                            2 => "W&#46; Vongpatanasin"
                            3 => "K&#46;C&#46; Ferdinand"
                            4 => "V&#46;N&#46; Pavlik"
                            5 => "B&#46;M&#46; Egan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/HYP.0000000000000203"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hypertension"
                        "fecha" => "2022"
                        "volumen" => "79"
                        "paginaInicial" => "e1"
                        "paginaFinal" => "e14"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34615363"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adherence to single-pill versus free-equivalent combination therapy in hypertension&#46; A systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "G&#46; Parati"
                            1 => "S&#46; Kjeldsen"
                            2 => "A&#46; Coca"
                            3 => "W&#46;C&#46; Cushman"
                            4 => "J&#46; Wang"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/HYPERTENSIONAHA.120.15781"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hypertension"
                        "fecha" => "2021"
                        "volumen" => "77"
                        "paginaInicial" => "692"
                        "paginaFinal" => "705"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33390044"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Documento de la Sociedad Espa&#241;ola de Nefrolog&#237;a sobre las gu&#237;as KDIGO para la evaluaci&#243;n y el tratamiento de la enfermedad renal cr&#243;nica"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Gorostidi"
                            1 => "R&#46; Santamar&#237;a"
                            2 => "R&#46; Alc&#225;zar"
                            3 => "G&#46; Fern&#225;ndez-Fresnedo"
                            4 => "J&#46;M&#46; Galcer&#225;n"
                            5 => "M&#46; Goicoechea"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3265/Nefrologia.pre2014.Feb.12464"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nefrologia"
                        "fecha" => "2014"
                        "volumen" => "34"
                        "paginaInicial" => "302"
                        "paginaFinal" => "316"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24798565"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Sick individuals and sick populations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "G&#46; Rose"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/ije/14.1.32"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Epidemiol"
                        "fecha" => "1985"
                        "volumen" => "14"
                        "paginaInicial" => "32"
                        "paginaFinal" => "38"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3872850"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "&#171;Mejores inversiones&#187; y otras intervenciones recomendadas para la prevenci&#243;n y el control de las enfermedades no transmisible&#46; Lucha contra las ENT"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Organizaci&#243;n Mundial de la Salud"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "WWW" => array:2 [
                        "link" => "https&#58;&#47;&#47;apps&#46;who&#46;int&#47;iris&#47;bitstream&#47;handle&#47;10665&#47;259351&#47;WHO-NMH-NVI-17&#46;9-spa&#46;pdf&#63;sequence&#61;1"
                        "fecha" => "2017"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "El paquete t&#233;cnico SAFER&#46; Un mundo libre de los da&#241;os relacionados con el alcohol"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Organizaci&#243;n Panamericana de la Salud"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "WWW" => array:2 [
                        "link" => "https&#58;&#47;&#47;iris&#46;paho&#46;org&#47;bitstream&#47;handle&#47;10665&#46;2&#47;51867&#47;9879275321959&#95;spa&#46;pdf&#63;sequence&#61;5&#38;isAllowed&#61;y"
                        "fecha" => "2020"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "WHO global air quality guidelines&#46; Particulate matter &#40;PM2&#46;5 and PM10&#41;&#44; ozone&#44; nitrogen dioxide&#44; sulfur dioxide and carbon monoxide"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "World Health Organization"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "2021"
                        "editorial" => "WHO"
                        "editorialLocalizacion" => "Geneva"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Regional Office for Europe&#46; Environmental noise guidelines for the European Region &#40;2018&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "World Health Organization"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "WWW" => array:2 [
                        "link" => "https&#58;&#47;&#47;www&#46;sanidad&#46;gob&#46;es&#47;profesionales&#47;saludPublica&#47;prevPromocion&#47;Prevencion&#47;alcohol&#47;docs&#47;ConsumoAlcohol&#95;DecisoresPoliticos&#46;pdf"
                        "fecha" => "2018"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consumo de alcohol&#58; Informaci&#243;n para decisores pol&#237;ticos&#46; &#191;Qu&#233; pueden hacer las administraciones p&#250;blicas&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Ministerio de Sanidad"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "WWW" => array:2 [
                        "link" => "https&#58;&#47;&#47;www&#46;sanidad&#46;gob&#46;es&#47;profesionales&#47;saludPublica&#47;prevPromocion&#47;Prevencion&#47;alcohol&#47;docs&#47;ConsumoAlcohol&#95;DecisoresPoliticos&#46;pdf"
                        "fecha" => "2021"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Exposure to aircraft and road traffic noise and associations with heart disease and stroke in six European countries&#58; a cross-sectional study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Floud"
                            1 => "M&#46; Blangiardo"
                            2 => "C&#46; Clark"
                            3 => "K&#46; de Hoogh"
                            4 => "W&#46; Babisch"
                            5 => "D&#46; Houthuijs"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1476-069X-12-89"
                      "Revista" => array:5 [
                        "tituloSerie" => "Environ Health"
                        "fecha" => "2013"
                        "volumen" => "12"
                        "paginaInicial" => "89"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24131577"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Convenio Marco de la OMSpara el Control del Tabaco"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Organizaci&#243;n Mundial de la Salud"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "WWW" => array:2 [
                        "link" => "https&#58;&#47;&#47;apps&#46;who&#46;int&#47;iris&#47;bitstream&#47;handle&#47;10665&#47;42813&#47;9243591010&#46;pdf&#63;sequence&#61;1"
                        "fecha" => "2003"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/25299123/0000003400000004/v2_202311240533/S2529912322000419/v2_202311240533/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "63722"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Special Article"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/25299123/0000003400000004/v2_202311240533/S2529912322000419/v2_202311240533/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912322000419?idApp=UINPBA00004N"
]

Article information

ISSN: 25299123
Original language: English

DOI:10.1016/j.artere.2022.06.007

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	3	0	3
2024 October	19	5	24
2024 September	51	13	64
2024 August	45	8	53
2024 July	21	7	28
2024 June	22	3	25
2024 May	9	4	13
2024 April	27	9	36
2024 March	34	6	40
2024 February	43	4	47
2024 January	20	4	24
2023 December	45	5	50
2023 November	12	4	16
2023 October	11	3	14
2023 September	6	2	8
2023 August	12	1	13
2023 July	9	1	10

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter